QUARTERLY REPORT

Q2 2020 — Form 10-Q

Q2 2020PDF · 54 pages621 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 	10-Q
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended 	June 30, 2020
OR
☐☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______ to ______
Commission File No. 	1-6571
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey 	22-1918501
(State or other jurisdiction of incorporation) 	(I.R.S Employer Identification No.)
2000 Galloping Hill Road
Kenilworth 	New Jersey 	07033
(Address of principal executive offices) (zip code)
(Registrant’s telephone number, including area code) 	(908) 	740-4000
Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. 	Yes 	☒	☒ 	No 	☐	☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). 	Yes 	☒	☒ 	No 	☐	☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth
company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
(Check one):
Large accelerated filer 	☒	☒ 	Accelerated filer 	☐	☐
Non-accelerated filer 	☐	☐ 	Smaller reporting company 	☐	☐
Emerging growth company 	☐	☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. 	☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes 	☐ 	No 	☒	☒
Securities Registered pursuant to Section 12(b) of the Act:
Title of each class 	Trading Symbol(s) 	Name of each exchange on which registered
Common Stock ($0.50 par value) 	MRK 	New York Stock Exchange
1.125% Notes due 2021 	MRK/21 	New York Stock Exchange
0.500% Notes due 2024 	MRK 24 	New York Stock Exchange
1.875% Notes due 2026 	MRK/26 	New York Stock Exchange
2.500% Notes due 2034 	MRK/34 	New York Stock Exchange
1.375% Notes due 2036 	MRK 36A 	New York Stock Exchange
The number of shares of common stock outstanding as of the close of business on 	July 31, 2020: 	2,529,241,070

-- 1 of 54 --

Table of Contents
Page No.
PART I 	FINANCIAL INFORMATION 	3
Item 1. 	Financial Statements 	3
Condensed Consolidated Statement of Income 	3
Condensed Consolidated Statement of Comprehensive Income 	3
Condensed Consolidated Balance Sheet 	4
Condensed Consolidated Statement of Cash Flows 	5
Notes to Condensed Consolidated Financial Statements 	6
Item 2. 	Management’s Discussion and Analysis of Financial Condition and Results of Operations 	31
Item 4. 	Controls and Procedures 	47
Cautionary Factors That May Affect Future Results 	47
PART II 	OTHER INFORMATION 	47
Item 1. 	Legal Proceedings 	47
Item 1A. 	Risk Factors 	47
Item 6. 	Exhibits 	48
Signatures 	49

-- 2 of 54 --

Part I - Financial Information
Item 1. Financial Statements
MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF INCOME
(Unaudited, $ in millions except per share amounts)
Three Months Ended
June 30,
Six Months Ended
June 30,
2020 	2019 	2020 	2019
Sales 	$ 	10,872 	$ 	11,760 	$ 	22,929 	$ 	22,575
Costs, Expenses and Other
Cost of sales 	3,159 	3,401 	6,471 	6,453
Selling, general and administrative 	2,378 	2,712 	4,933 	5,138
Research and development 	2,123 	2,189 	4,331 	4,119
Restructuring costs 	83 	59 	155 	212
Other (income) expense, net 	(390) 	140 	(318) 	327
7,353 	8,501 	15,572 	16,249
Income Before Taxes 	3,519 	3,259 	7,357 	6,326
Taxes on Income 	509 	615 	1,128 	820
Net Income 	3,010 	2,644 	6,229 	5,506
Less: Net Income (Loss) Attributable to Noncontrolling Interests 	8 	(26) 	8 	(79)
Net Income Attributable to Merck & Co., Inc. 	$ 	3,002 	$ 	2,670 	$ 	6,221 	$ 	5,585
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common
Shareholders 	$ 	1.19 	$ 	1.04 	$ 	2.46 	$ 	2.17
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc.
Common Shareholders 	$ 	1.18 	$ 	1.03 	$ 	2.45 	$ 	2.15
MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
(Unaudited, $ in millions)
Three Months Ended
June 30,
Six Months Ended
June 30,
2020 	2019 	2020 	2019
Net Income Attributable to Merck & Co., Inc. 	$ 	3,002 	$ 	2,670 	$ 	6,221 	$ 	5,585
Other Comprehensive (Loss) Income Net of Taxes:
Net unrealized loss on derivatives, net of reclassifications 	(120) 	(52) 	(16) 	(100)
Net unrealized gain (loss) on investments, net of reclassifications 	— 	44 	(18) 	126
Benefit plan net gain and prior service credit, net of amortization 	39 	11 	99 	26
Cumulative translation adjustment 	79 	(19) 	(265) 	131
(2) 	(16) 	(200) 	183
Comprehensive Income Attributable to Merck & Co., Inc. 	$ 	3,000 	$ 	2,654 	$ 	6,021 	$ 	5,768
The accompanying notes are an integral part of these condensed consolidated financial statements.
- 	3 	-

-- 3 of 54 --

MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEET
(Unaudited, $ in millions except per share amounts)
June 30, 2020 	December 31, 2019
Assets
Current Assets
Cash and cash equivalents 	$ 	11,103 	$ 	9,676
Short-term investments 	— 	774
Accounts receivable (net of allowance for doubtful accounts of $90 in 2020
and $86 in 2019) 	7,577 	6,778
Inventories (excludes inventories of $1,921 in 2020 and $1,480 in 2019
classified in Other assets - see Note 6) 	6,056 	5,978
Other current assets 	4,607 	4,277
Total current assets 	29,343 	27,483
Investments 	1,251 	1,469
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,182
in 2020 and $17,686 in 2019 	15,789 	15,053
Goodwill 	20,067 	19,425
Other Intangibles, Net 	16,566 	14,196
Other Assets 	7,599 	6,771
$ 	90,615 	$ 	84,397
Liabilities and Equity
Current Liabilities
Loans payable and current portion of long-term debt 	$ 	4,718 	$ 	3,610
Trade accounts payable 	3,448 	3,738
Accrued and other current liabilities 	11,182 	12,549
Income taxes payable 	1,266 	736
Dividends payable 	1,564 	1,587
Total current liabilities 	22,178 	22,220
Long-Term Debt 	26,156 	22,736
Deferred Income Taxes 	2,091 	1,470
Other Noncurrent Liabilities 	12,446 	11,970
Merck & Co., Inc. Stockholders’ Equity
Common stock, $0.50 par value
Authorized - 6,500,000,000 shares
Issued - 3,577,103,522 shares in 2020 and 2019 	1,788 	1,788
Other paid-in capital 	39,373 	39,660
Retained earnings 	49,724 	46,602
Accumulated other comprehensive loss 	(6,393) 	(6,193)
84,492 	81,857
Less treasury stock, at cost:
1,047,935,095 shares in 2020 and 1,038,087,496 shares in 2019 	56,850 	55,950
Total Merck & Co., Inc. stockholders’ equity 	27,642 	25,907
Noncontrolling Interests 	102 	94
Total equity 	27,744 	26,001
$ 	90,615 	$ 	84,397
The accompanying notes are an integral part of this condensed consolidated financial statement.
- 	4 	-

-- 4 of 54 --

MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(Unaudited, $ in millions)
Six Months Ended
June 30,
2020 	2019
Cash Flows from Operating Activities
Net income 	$ 	6,229 	$ 	5,506
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 	1,869 	1,871
Intangible asset impairment charges 	20 	252
Deferred income taxes 	122 	(149)
Share-based compensation 	229 	204
Other 	(202) 	114
Net changes in assets and liabilities 	(4,193) 	(3,378)
Net Cash Provided by Operating Activities 	4,074 	4,420
Cash Flows from Investing Activities
Capital expenditures 	(1,654) 	(1,377)
Purchases of securities and other investments 	(77) 	(1,810)
Proceeds from sales of securities and other investments 	1,892 	4,935
Acquisition of ArQule, Inc., net of cash acquired 	(2,545) 	—
Acquisition of Antelliq Corporation, net of cash acquired 	— 	(3,620)
Other acquisitions, net of cash acquired 	(321) 	(270)
Other 	195 	85
Net Cash Used in Investing Activities 	(2,510) 	(2,057)
Cash Flows from Financing Activities
Net change in short-term borrowings 	1,967 	(3,532)
Payments on debt 	(1,952) 	—
Proceeds from issuance of debt 	4,445 	4,958
Purchases of treasury stock 	(1,281) 	(2,325)
Dividends paid to stockholders 	(3,128) 	(2,896)
Proceeds from exercise of stock options 	40 	304
Other 	(444) 	(207)
Net Cash Used in Financing Activities 	(353) 	(3,698)
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash 	2 	28
Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash 	1,213 	(1,307)
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted
cash of $258 million at January 1, 2020 included in Other Assets) 	9,934 	7,967
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash
of $44 million at June 30, 2020 included in Other Assets) 	$ 	11,147 	$ 	6,660
The accompanying notes are an integral part of this condensed consolidated financial statement.
- 	5 	-

-- 5 of 54 --

Notes to Condensed Consolidated Financial Statements (unaudited)
1. 	Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of Merck & Co., Inc. (Merck or the Company) have been prepared pursuant
to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in
the United States (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the
audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 26, 2020.
The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all
adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature.
Planned Spin-Off of Women’s Health, Legacy Brands and Biosimilars into New Company
In February 2020, Merck announced its intention to spin-off products from its women’s health, legacy brands and biosimilars businesses into a new,
independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon’s publicly traded stock to Company shareholders. The
distribution is expected to qualify as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The legacy brands included in the
transaction consist of dermatology, non-opioid pain, respiratory, and select cardiovascular products including 	Zetia 	(ezetimibe) and 	Vytorin 	(ezetimibe and
simvastatin), as well as the rest of Merck’s diversified brands franchise. Merck’s existing research pipeline programs will continue to be owned and developed
within Merck as planned. Organon will have development capabilities initially focused on late-stage development and life-cycle management and is expected over
time to develop research capabilities in selected therapeutic areas. The spin-off is expected to be completed in the first half of 2021, subject to market and certain
other conditions. Subsequent to the spin-off, the historical results of the women’s health, legacy brands and biosimilars businesses will be reflected as discontinued
operations in the Company’s consolidated financial statements.
Recently Adopted Accounting Standards
In June 2016, the Financial Accounting Standards Board (FASB) issued new guidance on the accounting for credit losses on financial instruments. The
new guidance introduces an expected loss model for estimating credit losses, replacing the incurred loss model. The new guidance also changes the impairment
model for available-for-sale debt securities, requiring the use of an allowance to record estimated credit losses (and subsequent recoveries). The Company adopted
the new guidance effective January 1, 2020. There was no impact to the Company’s consolidated financial statements upon adoption.
In November 2018, the FASB issued new guidance for collaborative arrangements intended to reduce diversity in practice by clarifying whether certain
transactions between collaborative arrangement participants should be accounted for under revenue recognition guidance (ASC 606). The Company adopted the
new guidance effective January 1, 2020, which resulted in minor changes to the presentation of information related to the Company’s collaborative arrangements.
Recently Issued Accounting Standards Not Yet Adopted
In December 2019, the FASB issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the
accounting for income taxes by removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities; clarifying guidance primarily related
to evaluating the step-up tax basis for goodwill in a business combination; and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The
amended guidance is effective for interim and annual periods in 2021. Early adoption is permitted. The amendments in the new guidance are to be applied on a
retrospective basis, on a modified retrospective basis through a cumulative-effect adjustment to retained earnings or prospectively, depending on the amendment.
The Company is currently evaluating the impact of adoption on its consolidated financial statements.
In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity
method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring
certain purchased options and forward contracts to acquire investments. The new guidance is effective for interim and annual periods in 2021 and is to be applied
prospectively. Early adoption is permitted. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on
financial reporting. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions
affected by reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020
through December 31, 2022. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
- 	6 	-

-- 6 of 54 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
2. 	Acquisitions, Research Collaborations and License Agreements
The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to
complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third
party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development.
The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its
portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial
results of the acquired entity are not significant when compared with the Company’s financial results.
In July 2020, Merck acquired the U.S. rights to Sentinel Flavor Tabs and Sentinel Spectrum Chews from Virbac Corporation for approximately 	$400
million. Sentinel products provide protection against common parasites in dogs. The transaction will be accounted for as an acquisition of an asset. There are no
future contingent payments associated with the acquisition.
Also, in July 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback Bio), a closely held biotechnology company, closed a collaboration
agreement to develop MK-4482 (formerly known as EIDD-2801), an orally available antiviral candidate currently in clinical development for the treatment of
patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize MK-4482 and related molecules. Under the terms of the
agreement, Ridgeback Bio received an upfront payment and also is eligible to receive future contingent payments dependent upon the achievement of certain
developmental and regulatory approval milestones, as well as a share of the net profits of MK-4482 and related molecules, if approved. Merck and Ridgeback are
committed to ensure that any medicines developed for SARS-CoV-2 (the causative agent of COVID-19) will be accessible and affordable globally.
In June 2020, Merck acquired privately held Themis Bioscience GmbH (Themis), a company focused on vaccines and immune-modulation therapies
for infectious diseases and cancer for 	$366 million 	in cash. Merck may make additional contingent payments of up to 	$740 million, including up to 	$80 million 	for
development milestones, up to 	$260 million 	for regulatory approval milestones, and up to 	$400 million 	for commercial milestones. Themis has a broad pipeline of
vaccine candidates and immune-modulatory therapies developed using its innovative measles virus vector platform based on a vector originally developed by
scientists at the Institut Pasteur and licensed exclusively to Themis for select viral indications. The acquisition builds upon an ongoing collaboration between the
two companies to develop vaccine candidates using the measles virus vector platform and is expected to accelerate the development of Themis’ COVID-19 vaccine
candidate (V591). V591 is in preclinical development and clinical studies are planned to start in the third quarter of 2020. The transaction was accounted for as an
acquisition of a business. The Company determined the fair value of the contingent consideration was 	$97 million 	at the acquisition date utilizing a probability-
weighted estimated cash flow stream using an appropriate discount rate dependent on the nature and timing of the milestone payment. Merck recognized intangible
assets for in-process research and development (IPR&D) of 	$136 million, cash of 	$62 million, deferred tax assets of 	$72 million 	and other net liabilities of 	$22
million. The excess of the consideration transferred over the fair value of net assets acquired of 	$215 million 	was recorded as goodwill that was allocated to the
Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&D were determined using an
income approach. Actual cash flows are likely to be different than those assumed. In connection with the transaction, Merck has entered into a memorandum of
understanding that reflects the parties’ commitments to address the COVID-19 pandemic by developing, manufacturing and distributing the vaccine on a global
basis and with pricing that makes the vaccine both available around the world and accessible to those who need it.
In May 2020, Merck and the International AIDS Vaccine Initiative, Inc. (IAVI), a nonprofit scientific research organization dedicated to addressing
urgent, unmet global health challenges, announced a new collaboration to develop V590, an investigational vaccine against SARS-CoV-2 being studied for the
prevention of COVID-19. This vaccine candidate will use the recombinant vesicular stomatitis virus (rVSV) technology that is the basis for Merck’s approved
Ebola Zaire virus vaccine, 	Ervebo 	(Ebola Zaire Vaccine, Live), which was the first rVSV vaccine approved for use in humans. Under the terms of the agreement,
Merck made an upfront payment of 	$6.5 million 	and may make additional contingent payments of up to 	$100 million 	for sales-based milestones, as well as royalty
payments. Merck has also signed an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant
Secretary for Preparedness and Response within an agency of the United States Department of Health and Human Services, to provide initial funding support for
this effort. Under the agreement, IAVI and Merck will work together to advance the development and global clinical evaluation of a SARS-CoV-2 vaccine
candidate designed and engineered by IAVI scientists. The vaccine candidate is in preclinical development, and clinical studies are planned to start later in 2020.
Merck will lead regulatory filings globally. Both organizations will work together to develop the vaccine and make it accessible and affordable globally, if
approved.
In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and
development for the treatment of patients with cancer and other diseases. Total consideration paid of 	$2.7 billion 	included 	$138 million 	of share-based
compensation payments to settle equity awards attributable to precombination
- 	7 	-

-- 7 of 54 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
service and cash paid for transaction costs on behalf of ArQule. The Company incurred 	$95 million 	of transaction costs directly related to the acquisition of
ArQule, consisting almost entirely of share-based compensation payments to settle non-vested equity awards attributable to postcombination service. These costs
were included in 	Selling, general and administrative 	expenses in the first 	six 	months of 2020. ArQule’s lead investigational candidate, MK-1026 (formerly ARQ
531), is a novel, oral Bruton’s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies.
The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:
($ in millions) 	January 16, 2020
Cash and cash equivalents 	$ 	145
IPR&D MK-1026 (formerly ARQ 531) 	(1) 	2,280
IPR&D MK-7075 (formerly ARQ 092) 	(1) 	170
Licensing arrangement for ARQ 087 	80
Deferred income tax liabilities 	(434)
Other assets and liabilities, net 	35
Total identifiable net assets 	2,276
Goodwill 	(2) 	414
Consideration transferred 	$ 	2,690
(1) 	The estimated fair values of the identifiable intangible assets related to in-process research and development (IPR&D) were determined using an income approach. The future net cash flows
were discounted to present value utilizing a discount rate of 	12.5%. Actual cash flows are likely to be different than those assumed.
(2) 	The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.
On April 1, 2019, Merck acquired Antelliq Corporation (Antelliq), a leader in digital animal identification, traceability and monitoring solutions. These
solutions help veterinarians, farmers and pet owners gather critical data to improve management, health and well-being of livestock and pets. Merck paid 	$2.3
billion 	to acquire all outstanding shares of Antelliq and spent 	$1.3 billion 	to repay Antelliq’s debt. The transaction was accounted for as an acquisition of a
business.
The estimated fair value of assets acquired and liabilities assumed from Antelliq is as follows:
($ in millions) 	April 1, 2019
Cash and cash equivalents 	$ 	31
Accounts receivable 	73
Inventories 	93
Property, plant and equipment 	60
Identifiable intangible assets (useful lives ranging from 18-24 years) 	(1) 	2,689
Deferred income tax liabilities 	(589)
Other assets and liabilities, net 	(82)
Total identifiable net assets 	2,275
Goodwill 	(2) 	1,376
Consideration transferred 	$ 	3,651
(1) 	The estimated fair values of identifiable intangible assets relate primarily to trade names and were determined using an income approach. The future net cash flows were discounted to
present value utilizing a discount rate of 	11.5%. Actual cash flows are likely to be different than those assumed.
(2) 	The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Animal Health segment. The goodwill is not deductible
for tax purposes.
The Company’s results for the second quarter of 2019 include two months of activity for Antelliq. The Company incurred 	$47 million 	of transaction
costs directly related to the acquisition of Antelliq, consisting largely of advisory fees, which are reflected in 	Selling, general and administrative 	expenses in the
first 	six 	months of 2019.
Also in April 2019, Merck acquired Immune Design, a late-stage immunotherapy company employing next-generation 	in vivo 	approaches to enable the
body’s immune system to fight disease, for 	$301 million 	in cash. The transaction was accounted for as an acquisition of a business. Merck recognized intangible
assets of 	$156 million, cash of 	$83 million 	and other net assets of 	$42 million. The excess of the consideration transferred over the fair value of net assets acquired
of 	$20 million 	was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of
- 	8 	-

-- 8 of 54 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
the identifiable intangible assets related to IPR&D were determined using an income approach. Actual cash flows are likely to be different than those assumed.
3. 	Collaborative Arrangements
Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with
its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial
success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below.
AstraZeneca
In July 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize
AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Lynparza is an oral poly (ADP-ribose) polymerase (PARP) inhibitor currently approved for certain
types of advanced ovarian, breast, pancreatic and prostate cancers. The companies are jointly developing and commercializing Lynparza, both as monotherapy and
in combination trials with other potential medicines. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their
respective PD-1 and PD-L1 medicines, 	Keytruda 	(pembrolizumab) and Imfinzi. The companies will also jointly develop and commercialize AstraZeneca’s
Koselugo (selumetinib), an oral, selective inhibitor of MEK, part of the mitogen-activated protein kinase (MAPK) pathway, currently being developed for multiple
indications. In April 2020, Koselugo 	was approved by the U.S. Food and Drug Administration (FDA) for the treatment of pediatric patients two years of age and
older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. Under the terms of the agreement, AstraZeneca and Merck will
share the development and commercialization costs for Lynparza and Koselugo monotherapy and non-PD-L1/PD-1 combination therapy opportunities.
Profits from Lynparza and Koselugo product sales generated through monotherapies or combination therapies are shared equally. Merck will fund all
development and commercialization costs of 	Keytruda 	in combination with Lynparza or Koselugo. AstraZeneca will fund all development and commercialization
costs of Imfinzi in combination with Lynparza or Koselugo. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of
Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the
collaboration as part of 	Research and development 	expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized
as reductions to 	Research and development 	costs.
As part of the agreement, Merck made an upfront payment to AstraZeneca of 	$1.6 billion 	in 2017 and made payments of 	$750 million 	over a multi-year
period for certain license options. In addition, the agreement provides for additional contingent payments from Merck to AstraZeneca related to the successful
achievement of sales-based and regulatory milestones.
In the second quarter of 2020, Merck determined it was probable that sales of Lynparza in the future would trigger 	$400 million 	of sales-based
milestone payments from Merck to AstraZeneca. Accordingly, Merck recorded a 	$400 million 	liability and a corresponding increase to the intangible asset related
to Lynparza. Prior to 2020, Merck accrued sales-based milestone payments aggregating 	$1.0 billion 	related to Lynparza, of which 	$200 million 	and 	$250 million
was paid to AstraZeneca in 2019 and 2018, respectively, and 	$250 million 	was paid in the first 	six 	months of 2020. Potential future sales-based milestone payments
of 	$2.7 billion 	have not yet been accrued as they are not deemed by the Company to be probable at this time.
In the second quarter of 2020, Lynparza received regulatory approvals triggering capitalized milestone payments of 	$135 million 	from Merck to
AstraZeneca. In 2019 and 2018, Lynparza received regulatory approvals triggering capitalized milestone payments of 	$60 million 	and 	$140 million, respectively,
in the aggregate from Merck to AstraZeneca. Potential future regulatory milestone payments of 	$1.4 billion 	remain under the agreement.
The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was 	$1.3 billion 	at
June 30, 2020 	and is included in 	Other Intangibles, Net 	on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through
2028 as supported by projected future cash flows, subject to impairment testing.
- 	9 	-

-- 9 of 54 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30,
Six Months Ended
June 30,
($ in millions) 	2020 	2019 	2020 	2019
Alliance revenue - Lynparza 	$ 	178 	$ 	111 	$ 	323 	$ 	190
Cost of sales 	(1) 	137 	73 	164 	92
Selling, general and administrative 	39 	33 	72 	59
Research and development 	37 	33 	73 	78
($ in millions) 	June 30, 2020
December 31,
2019
Receivables from AstraZeneca included in 	Other current assets 	$ 	168 	$ 	128
Payables to AstraZeneca included in 	Accrued and other current liabilities 	(2) 	324 	577
Payables to AstraZeneca included in 	Other Noncurrent Liabilities 	(2) 	400 	—
(1) 	Represents amortization of capitalized milestone payments.
(2) 	Includes accrued milestone payments.
Eisai
In March 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of
Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Lenvima is currently approved for the treatment of certain types of thyroid
cancer, hepatocellular carcinoma, in combination with everolimus for certain patients with renal cell carcinoma, and in combination with 	Keytruda 	for the
treatment of certain patients with endometrial carcinoma. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as
monotherapy and in combination with 	Keytruda. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions), and Merck
and Eisai share profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses
incurred during co-development, including for studies evaluating Lenvima as monotherapy, are shared equally by the two companies and reflected in 	Research and
development 	expenses.
Under the agreement, Merck made an upfront payment to Eisai of 	$750 million 	and agreed to make payments of up to 	$650 million 	for certain option
rights through 2021 (of which 	$325 million 	was paid in March 2019, 	$200 million 	was paid in March 2020 and 	$125 million 	is expected to be paid in March 2021).
In addition, the agreement provides for additional contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory
milestones.
In the second quarter of 2020, Merck determined it was probable that sales of Lenvima in the future would trigger sales-based milestone payments
aggregating 	$370 million 	from Merck to Eisai. Accordingly, Merck recorded a 	$370 million 	liability and a corresponding increase to the intangible asset related to
Lenvima. Prior to 2020, Merck accrued sales-based milestone payments aggregating 	$950 million. Of these amounts, 	$50 million 	was paid to Eisai in 2019 and an
additional 	$500 million 	was paid in the first 	six 	months of 2020. Potential future sales-based milestone payments of 	$2.7 billion 	have not yet been accrued as they
are not deemed by the Company to be probable at this time.
In 2018, Lenvima received regulatory approvals triggering capitalized milestone payments of 	$250 million 	in the aggregate from Merck to Eisai.
Potential future regulatory milestone payments of 	$135 million 	remain under the agreement.
The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was 	$1.2 billion 	at 	June 30,
2020 	and is included in 	Other Intangibles, Net 	on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2026 as
supported by projected future cash flows, subject to impairment testing.
- 	10 	-

-- 10 of 54 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30,
Six Months Ended
June 30,
($ in millions) 	2020 	2019 	2020 	2019
Alliance revenue - Lenvima 	$ 	151 	$ 	97 	$ 	279 	$ 	171
Cost of sales 	(1) 	135 	23 	170 	74
Selling, general and administrative 	19 	19 	31 	38
Research and development 	56 	62 	120 	109
($ in millions) 	June 30, 2020
December 31,
2019
Receivables from Eisai included in 	Other current assets 	$ 	173 	$ 	150
Payables to Eisai included in 	Accrued and other current liabilities 	(2) 	325 	700
Payables to Eisai included in 	Other Noncurrent Liabilities 	(3) 	570 	525
(1) 	Represents amortization of capitalized milestone payments.
(2) 	Includes accrued milestone and future option payments.
(3) 	Includes accrued milestone payments.
Bayer AG
In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate
cyclase (sGC) modulators including Bayer’s Adempas (riociguat), which is approved to treat pulmonary arterial hypertension and chronic thromboembolic
pulmonary hypertension. The two companies have implemented a joint development and commercialization strategy. The collaboration also includes clinical
development of Bayer’s vericiguat, which is in development for the potential treatment of worsening heart failure. Vericiguat is currently under review by the
FDA. Under the agreement, Bayer leads commercialization of Adempas in the Americas, while Merck leads commercialization in the rest of the world. For
vericiguat, if approved, Bayer will lead commercialization in the rest of world and Merck will lead in the Americas. Both companies share in development costs
and profits on sales and have the right to co-promote in territories where they are not the lead. Merck records sales of Adempas in its marketing territories, as well
as alliance revenue, which is Merck’s share of profits from the sale of Adempas in Bayer’s marketing territories. In addition, the agreement provides for additional
contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones.
Prior to 2020, Merck accrued 	$725 million 	of sales-based milestone payments for this collaboration, of which 	$350 million 	was paid to Bayer in 2018.
There is an additional 	$400 million 	potential future sales-based milestone payment that has not yet been accrued as it is not deemed by the Company to be probable
at this time.
The intangible asset balance related to this collaboration (which includes the acquired intangible asset balance, as well as capitalized sales-based
milestone payments) was 	$832 million 	at 	June 30, 2020 	and is included in 	Other Intangibles, Net 	on the Consolidated Balance Sheet. The amount is being
amortized over its estimated useful life through 2027 as supported by projected future cash flows, subject to impairment testing.
- 	11 	-

-- 11 of 54 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30,
Six Months Ended
June 30,
($ in millions) 	2020 	2019 	2020 	2019
Alliance revenue - Adempas 	$ 	79 	$ 	51 	$ 	133 	$ 	94
Net sales of Adempas recorded by Merck 	57 	53 	113 	100
Total sales 	$ 	136 	$ 	104 	$ 	246 	$ 	194
Cost of sales 	(1) 	28 	29 	57 	58
Selling, general and administrative 	17 	11 	28 	20
Research and development 	16 	32 	41 	62
($ in millions) 	June 30, 2020
December 31,
2019
Receivables from Bayer included in 	Other current assets 	$ 	62 	$ 	49
Payables to Bayer included in 	Other Noncurrent Liabilities 	(2) 	375 	375
(1) 	Includes amortization of intangible assets.
(2) 	Represents accrued milestone payment.
4. 	Restructuring
In early 2019, Merck approved a new global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further
optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. This program is a continuation of the Company’s
plant rationalization, builds on prior restructuring programs and does not include any actions associated with the planned spin-off of Organon. As the Company
continues to evaluate its global footprint and overall operating model, it subsequently identified additional actions under the Restructuring Program, and could
identify further actions over time. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of
2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately 	$2.5 billion. The Company
estimates that approximately 	60% 	of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-
down costs. Approximately 	40% 	of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or
divested. The Company expects to record charges of approximately 	$800 million 	in 	2020 	related to the Restructuring Program. Actions under previous global
restructuring programs have been substantially completed.
The Company recorded total pretax costs of 	$150 million 	and 	$159 million 	in the 	second 	quarter of 	2020 	and 	2019, respectively, and 	$318 million 	and
$346 million 	for the first 	six 	months of 2020 and 2019, respectively, related to restructuring program activities. Since inception of the Restructuring Program
through 	June 30, 2020, Merck has recorded total pretax accumulated costs of approximately 	$1.2 billion. For segment reporting, restructuring charges are
unallocated expenses.
The following tables summarize the charges related to restructuring program activities by type of cost:
Three Months Ended June 30, 2020 	Six Months Ended June 30, 2020
($ in millions)
Separation
Costs
Accelerated
Depreciation 	Other 	Total
Separation
Costs
Accelerated
Depreciation 	Other 	Total
Cost of sales 	$ 	— 	$ 	31 	$ 	(6) 	$ 	25 	$ 	— 	$ 	56 	$ 	37 	$ 	93
Selling, general and
administrative 	— 	11 	— 	11 	— 	22 	— 	22
Research and development 	— 	31 	— 	31 	— 	48 	— 	48
Restructuring costs 	35 	— 	48 	83 	82 	— 	73 	155
$ 	35 	$ 	73 	$ 	42 	$ 	150 	$ 	82 	$ 	126 	$ 	110 	$ 	318
Three Months Ended June 30, 2019 	Six Months Ended June 30, 2019
($ in millions)
Separation
Costs
Accelerated
Depreciation 	Other 	Total
Separation
Costs
Accelerated
Depreciation 	Other 	Total
Cost of sales 	$ 	— 	$ 	64 	$ 	1 	$ 	65 	$ 	— 	$ 	98 	$ 	1 	$ 	99
Selling, general and
administrative 	— 	32 	— 	32 	— 	32 	— 	32
Research and development 	— 	2 	1 	3 	— 	2 	1 	3
Restructuring costs 	25 	— 	34 	59 	153 	— 	59 	212
$ 	25 	$ 	98 	$ 	36 	$ 	159 	$ 	153 	$ 	132 	$ 	61 	$ 	346
- 	12 	-

-- 12 of 54 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
Separation costs are associated with actual headcount reductions, as well as those headcount reductions which were probable and could be reasonably
estimated.
Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the
programs. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based
upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to
the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are
sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure
dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.
Other activity in 	2020 	and 	2019 	includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from
the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit
plans (see Note 11) and share-based compensation.
The following table summarizes the charges and spending relating to restructuring program activities for the 	six 	months ended 	June 30, 2020:
($ in millions)
Separation
Costs
Accelerated
Depreciation 	Other 	Total
Restructuring reserves January 1, 2020 	$ 	690 	$ 	— 	$ 	69 	$ 	759
Expense 	82 	126 	110 	318
(Payments) receipts, net 	(328) 	— 	(163) 	(491)
Non-cash activity 	— 	(126) 	34 	(92)
Restructuring reserves June 30, 2020 	(1) 	$ 	444 	$ 	— 	$ 	50 	$ 	494
(1) 	The remaining cash outlays are expected to be substantially completed by the end of 2023.
5. 	Financial Instruments
Derivative Instruments and Hedging Activities
The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets
and liabilities through operational means and through the use of various financial instruments, including derivative instruments.
A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives and
accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.
Foreign Currency Risk Management
The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of
future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.
The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar
value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the
Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are
expected to occur over its planning cycle, typically no more than 	two years 	into the future. The Company will layer in hedges over time, increasing the portion of
forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit
profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company
manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts and purchased collar options.
The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated
Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or 	Other comprehensive income 	(OCI),
depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash
flow hedges, the unrealized gains or losses on these contracts are recorded in 	Accumulated other comprehensive income 	(AOCI) and reclassified into 	Sales 	when
the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales,
unrealized gains or losses are recorded in 	Sales 	each period. The cash flows from both
- 	13 	-

-- 13 of 54 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
designated and non-designated contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. The Company does not enter
into derivatives for trading or speculative purposes.
The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary
assets and liabilities. The Company also uses a balance sheet risk management program to mitigate the exposure of net monetary assets that are denominated in a
currency other than a subsidiary’s functional currency from the effects of volatility in foreign exchange. In these instances, Merck principally utilizes forward
exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro and Japanese yen. For
exposures in developing country currencies, the Company will enter into forward contracts to partially offset the effects of exchange on exposures when it is
deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the
hedging instrument. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.
Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect
on the balance sheet date with the effects of changes in spot rates reported in 	Other (income) expense, net. The forward contracts are not designated as hedges and
are marked to market through 	Other (income) expense, net. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the
remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences
are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than 	one year.
The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates.
The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in
foreign currency translation adjustment within 	OCI 	and remain in 	AOCI 	until either the sale or complete or substantially complete liquidation of the subsidiary. The
Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components).
Changes in fair value of the excluded components are recognized in 	OCI. The Company recognizes in earnings the initial value of the excluded components on a
straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as
investing activities in the Condensed Consolidated Statement of Cash Flows.
Foreign exchange risk is also managed through the use of foreign currency debt. The Company’s senior unsecured euro-denominated notes have been
designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to
spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within 	OCI.
The effects of the Company’s net investment hedges on 	OCI 	and the Consolidated Statement of Income are shown below:
Amount of Pretax (Gain) Loss Recognized in Other
Comprehensive Income 	(1)
Amount of Pretax (Gain) Loss Recognized in 	Other
(income) expense, net 	for Amounts Excluded from
Effectiveness Testing
Three Months Ended June 30, 	Six Months Ended June 30,
Three Months Ended June
30, 	Six Months Ended June 30,
($ in millions) 	2020 	2019 	2020 	2019 	2020 	2019 	2020 	2019
Net Investment Hedging Relationships
Foreign exchange contracts 	$ 	8 	$ 	17 	$ 	5 	$ 	7 	$ 	(4) 	$ 	(8) 	$ 	(11) 	$ 	(15)
Euro-denominated notes 	72 	28 	21 	(2) 	— 	— 	— 	—
(1) 	No amounts were reclassified from AOCI into income related to the sale of a subsidiary.
Interest Rate Risk Management
The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes
and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that
would put principal capital at risk.
In 	February 	2020, 	five 	interest 	rate 	swaps 	with 	notional 	amounts 	of 	$250 	million 	each 	matured. 	These 	swaps 	effectively 	converted 	the
Company’s 	$1.25 billion, 	1.85% 	fixed-rate notes due 2020 to variable rate debt. At 	June 30, 2020, the Company was a party to 	14 	pay-floating, receive-fixed
interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as
detailed in the table below.
- 	14 	-

-- 14 of 54 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
June 30, 2020
($ in millions) 	Par Value of Debt
Number of Interest
Rate Swaps Held
Total Swap Notional
Amount
3.875% notes due 2021 	$ 	1,150 	5 	$ 	1,150
2.40% notes due 2022 	1,000 	4 	1,000
2.35% notes due 2022 	1,250 	5 	1,250
The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark London Interbank
Offered Rate (LIBOR) swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate are recorded in interest expense along with the
offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated
Statement of Cash Flows.
The table below presents the location of amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value
hedges:
Carrying Amount of Hedged Liabilities
Cumulative Amount of Fair Value Hedging
Adjustment Increase (Decrease) Included in the
Carrying Amount
($ in millions) 	June 30, 2020 	December 31, 2019 	June 30, 2020 	December 31, 2019
Balance Sheet Line Item in which Hedged Item is Included
Loans payable and current portion of long-term debt 	$ 	1,160 	$ 	1,249 	$ 	10 	$ 	(1)
Long-Term Debt 	2,318 	3,409 	71 	14
Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging
instruments and those that are not designated as hedging instruments:
June 30, 2020 	December 31, 2019
Fair Value of Derivative U.S. Dollar
Notional
Fair Value of Derivative U.S. Dollar
Notional	($ in millions) 	Balance Sheet Caption 	Asset 	Liability 	Asset 	Liability
Derivatives Designated as Hedging
Instruments
Interest rate swap contracts 	Other current assets 	$ 	10 	$ 	— 	$ 	1,150 	$ 	— 	$ 	— 	$ 	—
Interest rate swap contracts 	Other Assets 	72 	— 	2,250 	15 	— 	3,400
Interest rate swap contracts 	Accrued and other current liabilities 	— 	— 	— 	— 	1 	1,250
Foreign exchange contracts 	Other current assets 	83 	— 	4,959 	152 	— 	6,117
Foreign exchange contracts 	Other Assets 	70 	— 	1,993 	55 	— 	2,160
Foreign exchange contracts 	Accrued and other current liabilities 	— 	27 	1,884 	— 	22 	1,748
Foreign exchange contracts 	Other Noncurrent Liabilities 	— 	1 	11 	— 	1 	53
$ 	235 	$ 	28 	$ 	12,247 	$ 	222 	$ 	24 	$ 	14,728
Derivatives Not Designated as
Hedging Instruments
Foreign exchange contracts 	Other current assets 	$ 	93 	$ 	— 	$ 	5,324 	$ 	66 	$ 	— 	$ 	7,245
Foreign exchange contracts 	Accrued and other current liabilities 	— 	103 	5,865 	— 	73 	8,693
$ 	93 	$ 	103 	$ 	11,189 	$ 	66 	$ 	73 	$ 	15,938
$ 	328 	$ 	131 	$ 	23,436 	$ 	288 	$ 	97 	$ 	30,666
As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting
agreements with several of its financial institution counterparties (see 	Concentrations of Credit Risk 	below). The following table provides information on the
Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by
counterparty and cash collateral exchanged per the master agreements and related credit support annexes:
June 30, 2020 	December 31, 2019
($ in millions) 	Asset 	Liability 	Asset 	Liability
Gross amounts recognized in the condensed consolidated balance sheet 	$ 	328 	$ 	131 	$ 	288 	$ 	97
Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet 	(115) 	(115) 	(84) 	(84)
Cash collateral received 	(38) 	— 	(34) 	—
Net amounts 	$ 	175 	$ 	16 	$ 	170 	$ 	13
- 	15 	-

-- 15 of 54 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value or cash flow
hedging relationships:
Sales 	Other (income) expense, net 	(1)
Other comprehensive income
(loss) 	Sales
Other (income) expense,
net 	(1)
Other comprehensive
income (loss)
Three Months Ended June 30, 	Three Months Ended June 30, 	Three Months Ended June 30, 	Six Months Ended June 30, 	Six Months Ended June 30,
Six Months Ended June
30,
($ in millions) 	2020 	2019 	2020 	2019 	2020 	2019 	2020 	2019 	2020 	2019 	2020 	2019
Financial Statement Line Items in
which Effects of Fair Value or Cash
Flow Hedges are Recorded 	$ 	10,872 	$ 	11,760 	$ 	(390) 	$ 	140 	$ 	(2) 	$ 	(16) 	$ 	22,929 	$ 	22,575 	$ 	(318) 	$ 	327 	$ 	(200) 	$ 	183
(Gain) loss on fair value hedging
relationships
Interest rate swap contracts
Hedged items 	— 	— 	1 	55 	— 	— 	— 	— 	68 	88 	— 	—
Derivatives designated as hedging
instruments 	— 	— 	(8) 	(45) 	— 	— 	— 	— 	(76) 	(68) 	— 	—
Impact of cash flow hedging
relationships
Foreign exchange contracts
Amount of (loss) gain recognized
in 	OCI 	on derivatives 	— 	— 	— 	— 	(109) 	10 	— 	— 	— 	— 	69 	(2)
Increase (decrease) in 	Sales 	as a
result of 	AOCI 	reclassifications 	42 	75 	— 	— 	(42) 	(75) 	88 	119 	— 	— 	(88) 	(119)
Interest rate contracts
Amount of gain recognized in
Other (income) expense, net 	on
derivatives 	— 	— 	(1) 	(1) 	— 	— 	— 	— 	(2) 	(2) 	— 	—
Amount of loss recognized in
OCI 	on derivatives 	— 	— 	— 	— 	(1) 	(1) 	— 	— 	— 	— 	(2) 	(5)
(1) 	Interest expense is a component of 	Other (income) expense, net.
The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:
Amount of Derivative Pretax (Gain) Loss Recognized in Income
Three Months Ended June 30, 	Six Months Ended June 30,
($ in millions) 	Income Statement Caption 	2020 	2019 	2020 	2019
Derivatives Not Designated as Hedging Instruments
Foreign exchange contracts 	(1) 	Other (income) expense, net 	$ 	49 	$ 	2 	$ 	(131) 	$ 	120
Foreign exchange contracts 	(2) 	Sales 	4 	(6) 	(3) 	4
Interest rate contracts 	(3) 	Other (income) expense, net 	9 	— 	9 	—
(1) 	These derivative contracts mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange
rates.
(2) 	These derivative contracts serve as economic hedges of forecasted transactions.
(3) 	These derivatives serve as economic hedges against rising treasury rates.
At 	June 30, 2020, the Company estimates 	$9 million 	of pretax net unrealized gains on derivatives maturing within the next 12 months that hedge
foreign currency denominated sales over that same period will be reclassified from 	AOCI 	to 	Sales. The amount ultimately reclassified to 	Sales 	may differ as foreign
exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.
- 	16 	-

-- 16 of 54 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
Investments in Debt and Equity Securities
Information on investments in debt and equity securities is as follows:
June 30, 2020 	December 31, 2019
Amortized
Cost
Gross Unrealized Fair
Value
Amortized
Cost
Gross Unrealized Fair
Value	($ in millions) 	Gains 	Losses 	Gains 	Losses
U.S. government and agency securities 	$ 	74 	$ 	— 	$ 	— 	$ 	74 	$ 	266 	$ 	3 	$ 	— 	$ 	269
Foreign government bonds 	2 	— 	— 	2 	— 	— 	— 	—
Commercial paper 	— 	— 	— 	— 	668 	— 	— 	668
Corporate notes and bonds 	— 	— 	— 	— 	608 	13 	— 	621
Asset-backed securities 	— 	— 	— 	— 	226 	1 	— 	227
Total debt securities 	$ 	76 	$ 	— 	$ 	— 	$ 	76 	$ 	1,768 	$ 	17 	$ 	— 	$ 	1,785
Publicly traded equity securities 	(1) 	1,307 	838
Total debt and publicly traded equity securities 	$ 	1,383 	$ 	2,623
(1) 	Unrealized net (gains) losses recognized in 	Other (income) expense, net 	on equity securities still held at 	June 30, 2020 	were 	$(464) million 	and 	$(469) million 	in the 	second 	quarter and first
six 	months of 	2020, respectively. Unrealized net losses (gains) recognized in 	Other (income) expense, net 	on equity securities still held at 	June 30, 2019 	were 	$39 million 	and 	$(75) million 	in
the 	second 	quarter and first 	six 	months of 	2019, respectively.
At 	June 30, 2020 	and 	June 30, 2019, the Company also had 	$487 million 	and 	$465 million, respectively, of equity investments without readily
determinable fair values included in 	Other Assets. The Company recognizes unrealized gains on these equity investments based on favorable observable price
changes from transactions involving similar investments of the same investee and recognizes unrealized losses based on unfavorable observable price changes.
During the first 	six 	months of 2020, the Company recognized unrealized gains of 	$18 million 	and unrealized losses of 	$3 million 	in 	Other (income) expense, net
related to these equity investments held at 	June 30, 2020. During the first 	six 	months of 	2019, the Company recognized unrealized gains of 	$4 million 	and
unrealized losses of 	$10 million 	in 	Other (income) expense, net 	related to these investments held at 	June 30, 2019. Cumulative unrealized gains and cumulative
unrealized losses based on observable prices changes for investments in equity investments without readily determinable fair values still held at 	June 30, 2020 	were
$127 million 	and 	$24 million, respectively.
Fair Value Measurements
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most
advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value
hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs
used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest: 	Level 1 	- Quoted prices (unadjusted) in active markets for
identical assets or liabilities; 	Level 2 	- Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are
observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; 	Level 3 	- Unobservable inputs that are
supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow
methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires
significant judgment or estimation. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the
categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
- 	17 	-

-- 17 of 54 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
Fair Value Measurements Using 	Fair Value Measurements Using
Level 1 	Level 2 	Level 3 	Total 	Level 1 	Level 2 	Level 3 	Total
($ in millions) 	June 30, 2020 	December 31, 2019
Assets
Investments
Foreign government bonds 	$ 	— 	$ 	2 	$ 	— 	$ 	2 	$ 	— 	$ 	— 	$ 	— 	$ 	—
Commercial paper 	— 	— 	— 	— 	— 	668 	— 	668
Corporate notes and bonds 	— 	— 	— 	— 	— 	621 	— 	621
Asset-backed securities 	(1) 	— 	— 	— 	— 	— 	227 	— 	227
U.S. government and agency
securities 	— 	— 	— 	— 	— 	209 	— 	209
Publicly traded equity securities 	1,249 	— 	— 	1,249 	518 	— 	— 	518
1,249 	2 	— 	1,251 	518 	1,725 	— 	2,243
Other assets 	(2)
U.S. government and agency
securities 	74 	— 	— 	74 	60 	— 	— 	60
Publicly traded equity securities 	58 	— 	— 	58 	320 	— 	— 	320
132 	— 	— 	132 	380 	— 	— 	380
Derivative assets 	(3)
Forward exchange contracts 	— 	142 	— 	142 	— 	169 	— 	169
Purchased currency options 	— 	104 	— 	104 	— 	104 	— 	104
Interest rate swaps 	— 	82 	— 	82 	— 	15 	— 	15
— 	328 	— 	328 	— 	288 	— 	288
Total assets 	$ 	1,381 	$ 	330 	$ 	— 	$ 	1,711 	$ 	898 	$ 	2,013 	$ 	— 	$ 	2,911
Liabilities
Other liabilities
Contingent consideration 	$ 	— 	$ 	— 	$ 	798 	$ 	798 	$ 	— 	$ 	— 	$ 	767 	$ 	767
Derivative liabilities 	(3)
Forward exchange contracts 	— 	128 	— 	128 	— 	95 	— 	95
Written currency options 	— 	3 	— 	3 	— 	1 	— 	1
Interest rate swaps 	— 	— 	— 	— 	— 	1 	— 	1
— 	131 	— 	131 	— 	97 	— 	97
Total liabilities 	$ 	— 	$ 	131 	$ 	798 	$ 	929 	$ 	— 	$ 	97 	$ 	767 	$ 	864
(1) 	Primarily all of the asset-backed securities were highly rated (Standard & Poor’s rating of AAA and Moody’s Investors Service rating of Aaa), secured primarily by auto loan, credit card
and student loan receivables, with weighted-average lives of primarily 	5 	years or less.
(2) 	Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.
(3) 	The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not
significant.
As of 	June 30, 2020 	and 	December 31, 2019, 	Cash and cash equivalents 	included 	$10.4 billion 	and 	$8.9 billion 	of cash equivalents, respectively (which
would be considered Level 2 in the fair value hierarchy).
- 	18 	-

-- 18 of 54 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
Contingent Consideration
Summarized information about the changes in liabilities for contingent consideration associated with business acquisitions is as follows:
Six Months Ended June 30,
($ in millions) 	2020 	2019
Fair value January 1 	$ 	767 	$ 	788
Additions 	97 	—
Changes in estimated fair value 	(1) 	40 	50
Payments 	(106) 	(85)
Fair value June 30 	(2)(3) 	$ 	798 	$ 	753
(1) 	Recorded in 	Cost of sales, Research and development 	expenses, and 	Other (income) expense, net. Includes cumulative translation adjustments.
(2) 	Balance at 	June 30, 2020 	includes 	$138 million 	recorded as a current liability for amounts expected to be paid within the next 12 months.
(3) 	At 	June 30, 2020 	and 	December 31, 2019, 	$608 million 	and 	$625 million, respectively, of the liabilities relate to the termination of the Sanofi-Pasteur MSD joint venture in 2016. As part of
the termination, Merck recorded a liability for contingent future royalty payments of 	11.5% 	on net sales of all Merck products that were previously sold by the joint venture through
December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate of 	8% 	to present value
the cash flows.
The additions to contingent consideration in 2020 relate to the acquisition of Themis (see Note 2). The payments of contingent consideration in both
periods relate to liabilities recorded in connection with the termination of the Sanofi-Pasteur MSD joint venture in 2016.
Other Fair Value Measurements
Some of the Company’s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying
value, which approximates fair value due to their short-term nature.
The estimated fair value of loans payable and long-term debt (including current portion) at 	June 30, 2020, was 	$34.5 billion 	compared with a carrying
value of 	$30.9 billion 	and at 	December 31, 2019, was 	$28.8 billion 	compared with a carrying value of 	$26.3 billion. Fair value was estimated using recent
observable market prices and would be considered Level 2 in the fair value hierarchy.
Concentrations of Credit Risk
On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial
institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and
investments are placed in instruments that meet high credit quality standards as specified in the Company’s investment policy guidelines.
The majority of the Company’s accounts receivable arise from product sales in the United States, Europe and China and are primarily due from drug
wholesalers and retailers, hospitals, government agencies, managed health care providers and pharmacy benefit managers. The Company monitors the financial
performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to
monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets
and its business.
The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company
factored 	$1.9 billion 	and 	$2.7 billion 	of accounts receivable in the 	second 	quarter of 	2020 	and the fourth quarter of 	2019, respectively, under these factoring
arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the
Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related
to the factored receivables, which it then remits to the financial institutions. The net cash flows relating to these collections are reported as financing activities in
the Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was 	de minimis.
Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with
several of the Company’s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be
exchanged depending on the value of the derivative assets and liabilities, the Company’s credit rating, and the credit rating of the counterparty. Cash collateral
received by the Company from various counterparties was 	$38 million 	and 	$34 million 	at 	June 30, 2020 	and 	December 31, 2019, respectively. The obligation to
return such collateral is recorded in 	Accrued and other current liabilities. 	No 	cash collateral was advanced by the Company to counterparties as of 	June 30, 2020 	or
December 31, 2019.
- 	19 	-

-- 19 of 54 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
6. 	Inventories
Inventories consisted of:
($ in millions) 	June 30, 2020 	December 31, 2019
Finished goods 	$ 	2,032 	$ 	1,772
Raw materials and work in process 	5,874 	5,650
Supplies 	190 	207
Total (approximates current cost) 	8,096 	7,629
Decrease to LIFO cost 	(119) 	(171)
$ 	7,977 	$ 	7,458
Recognized as:
Inventories 	$ 	6,056 	$ 	5,978
Other assets 	1,921 	1,480
Amounts recognized as 	Other Assets 	are comprised almost entirely of raw materials and work in process inventories. At 	June 30, 2020 	and
December 31, 2019, these amounts included 	$1.7 billion 	and 	$1.3 billion, respectively, of inventories not expected to be sold within one year. In addition, these
amounts included 	$266 million 	and 	$168 million 	at 	June 30, 2020 	and 	December 31, 2019, respectively, of inventories produced in preparation for product
launches.
7. 	Long-Term Debt
In June 2020, the Company issued 	$4.5 billion 	principal amount of senior unsecured notes consisting of 	$1.0 billion 	of 	0.75% 	notes due 2026, 	$1.25
billion 	of 	1.45% 	notes due 2030, 	$1.0 billion 	of 	2.35% 	notes due 2040 and 	$1.25 billion 	of 	2.45% 	notes due 2050. Merck intends to use the net proceeds from the
offering for general corporate purposes, including without limitation the repayment of outstanding commercial paper borrowings and other indebtedness with
upcoming maturities.
8. 	Contingencies
The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual
property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is
unlikely that the resolution of these matters will be material to the Company’s financial condition, results of operations or cash flows.
Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a
possible loss or range of possible loss for such matters until the Company knows, among other factors, (i) what claims, if any, will survive dispositive motion
practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the
discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect
on the litigation.
The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated.
These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall
accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported.
Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a
loss contingency are accrued when probable and reasonably estimable.
The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such
decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of
the coverage that is available and, as such, has no insurance for most product liabilities.
Product Liability Litigation
Fosamax
As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving 	Fosamax 	(Fosamax 	Litigation). As of 	June 30,
2020, approximately 	3,590 	cases are pending against Merck in either federal or state court. Plaintiffs in the vast majority of these cases generally allege that they
sustained femur fractures and/or other bone injuries (Femur Fractures) in association with the use of 	Fosamax.
- 	20 	-

-- 20 of 54 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
All federal cases involving allegations of Femur Fractures have been or will be transferred to a multidistrict litigation in the District of New Jersey
(Femur Fracture MDL). In the only bellwether case tried to date in the Femur Fracture MDL, 	Glynn v. Merck, the jury returned a verdict in Merck’s favor. In
addition, in June 2013, the Femur Fracture MDL court granted Merck’s motion for judgment as a matter of law in the 	Glynn 	case and held that the plaintiff’s
failure to warn claim was preempted by federal law.
In August 2013, the Femur Fracture MDL court entered an order requiring plaintiffs in the Femur Fracture MDL to show cause why those cases
asserting claims for a femur fracture injury that took place prior to September 14, 2010, should not be dismissed based on the court’s preemption decision in the
Glynn 	case. Pursuant to the show cause order, in March 2014, the Femur Fracture MDL court dismissed with prejudice approximately 	650 	cases on preemption
grounds. Plaintiffs in approximately 	515 	of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit (Third Circuit). In March 2017, the
Third Circuit issued a decision reversing the Femur Fracture MDL court’s preemption ruling and remanding the appealed cases back to the Femur Fracture MDL
court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and
accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the
Supreme Court’s opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first
instance whether the plaintiffs’ state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. Briefing on the
issue is closed, and the parties await the decision of the District Court.
Accordingly, as of 	June 30, 2020, approximately 	970 	cases were actively pending in the Femur Fracture MDL.
As of 	June 30, 2020, approximately 	2,345 	cases alleging Femur Fractures have been filed in New Jersey state court and are pending before Judge James
Hyland in Middlesex County. The parties selected an initial group of cases to be reviewed through fact discovery, and Merck has continued to select additional
cases to be reviewed.
As of 	June 30, 2020, approximately 	275 	cases alleging Femur Fractures have been filed and are pending in California state court. All of the Femur
Fracture cases filed in California state court have been coordinated before a single judge in Orange County, California.
Additionally, there are 	four 	Femur Fracture cases pending in other state courts.
Discovery is presently stayed in the Femur Fracture MDL and in the state court in California. Merck intends to defend against these lawsuits.
Januvia/Janumet
As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving 	Januvia 	and/or 	Janumet. As of 	June 30, 2020,
Merck is aware of approximately 	1,440 	product users alleging that 	Januvia 	and/or 	Janumet 	caused the development of pancreatic cancer and other injuries.
Most claims have been filed in multidistrict litigation before the U.S. District Court for the Southern District of California (MDL). Outside of the MDL,
the majority of claims have been filed in coordinated proceedings before the Superior Court of California, County of Los Angeles (California State Court).
In November 2015, the MDL and California State Court–in separate opinions–granted summary judgment to defendants on grounds of federal
preemption.
Plaintiffs appealed in both forums. In November 2017, the U.S. Court of Appeals for the Ninth Circuit vacated the judgment and remanded for further
discovery. In November 2018, the California state appellate court reversed and remanded on similar grounds. In March 2019, the parties in the MDL and the
California coordinated proceedings agreed to coordinate and adopt a schedule for completing discovery on general causation and preemption issues and for
renewing summary judgment and 	Daubert 	motions. Under the stipulated case management schedule, the hearings for 	Daubert 	and summary judgment motions are
expected to take place in the second half of 2020.
As of 	June 30, 2020, 	six 	product users have claims pending against Merck in state courts other than California, including Illinois. In June 2017, the
Illinois trial court denied Merck’s motion for summary judgment based on federal preemption. Merck appealed, and the Illinois appellate court affirmed in
December 2018. Merck filed a petition for leave to appeal to the Illinois Supreme Court in February 2019. In April 2019, the Illinois Supreme Court stayed
consideration of the pending petition to appeal until the U.S. Supreme Court issued its opinion in 	Merck Sharp & Dohme Corp. v. Albrecht 	(relating to the
Fosamax 	matter discussed above). Merck filed the opinion in 	Albrecht 	with the Illinois Supreme Court in June 2019. The petition for leave to appeal was decided
in September 2019, in which the Illinois Supreme Court directed the intermediate appellate court to reconsider its earlier ruling. The Illinois Appellate Court issued
a favorable decision concluding, consistent with 	Albrecht, that preemption presents a legal question to be resolved by the court.
In addition to the claims noted above, the Company has agreed to toll the statute of limitations for approximately 	50 	additional claims. The Company
intends to continue defending against these lawsuits.
- 	21 	-

-- 21 of 54 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
Vioxx
As previously disclosed, Merck is a defendant in a lawsuit brought by the Attorney General of Utah alleging that Merck misrepresented the safety of
Vioxx. The lawsuit is pending in Utah state court. Utah seeks damages and penalties under the Utah False Claims Act. A bench trial in this matter has been
rescheduled for April 6, 2021.
Governmental Proceedings
On June 17, 2020, Merck received a Civil Investigative Demand (CID) from the U.S. Department of Justice. The CID requests answers to
interrogatories, as well as various documents, regarding temperature excursions at a third-party storage facility containing certain Merck products. Merck is
cooperating with the government’s investigation and intends to produce information and/or documents as necessary in response to the CID.
As previously disclosed, the Company’s subsidiaries in China have received and may continue to receive inquiries regarding their operations from
various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as
Chinese entities doing business with such companies. The Company’s policy is to cooperate with these authorities and to provide responses as appropriate.
As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition
and other governmental authorities in markets outside the United States. These authorities may include regulators, administrative authorities, and law enforcement
and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials,
inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those
proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.
Commercial and Other Litigation
Zetia 	Antitrust Litigation
As previously disclosed, Merck, MSD, Schering Corporation and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants
in putative class action and opt-out lawsuits filed in 2018 on behalf of direct and indirect purchasers of 	Zetia 	alleging violations of federal and state antitrust laws,
as well as other state statutory and common law causes of action. The cases have been consolidated for pretrial purposes in a federal multidistrict litigation before
Judge Rebecca Beach Smith in the Eastern District of Virginia. In December 2018, the court denied the Merck Defendants’ motions to dismiss or stay the direct
purchaser putative class actions pending bilateral arbitration. In August 2019, the district court adopted in full the report and recommendation of the magistrate
judge with respect to the Merck Defendants’ motions to dismiss on non-arbitration issues, thereby granting in part and denying in part Merck Defendants’ motions
to dismiss. In addition, in June 2019, the representatives of the putative direct purchaser class filed an amended complaint, and in August 2019, retailer opt-out
plaintiffs filed an amended complaint. The Merck Defendants moved to dismiss the new allegations in both complaints. In October 2019, the magistrate judge
issued a report and recommendation recommending that the district judge grant the motions in their entirety. In December 2019, the district court adopted this
report and recommendation in part. The district court granted the Merck Defendants’ motion to dismiss to the extent the motion sought dismissal of claims for
overcharges paid by entities that purchased generic ezetimibe from Par Pharmaceutical, Inc. (Par Pharmaceutical) and dismissed any claims for such overcharges.
In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. On June 18, 2020, the magistrate judge
issued a report and recommendation recommending that the district judge grant in part the direct purchasers’ motion for class certification and certify a class of 	35
direct purchasers. On July 2, 2020, defendants objected to the report and recommendation. The indirect purchasers’ class certification motion is still pending before
the magistrate judge. Trial in this matter has been rescheduled to begin on February 23, 2021.
Patent Litigation
From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market
generic forms of the Company’s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file
patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company’s patent rights may exist in other countries. The Company
intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of
such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for
these products and, with respect to products acquired through acquisitions, potentially significant intangible asset impairment charges.
Bridion 	— 	Between January and March 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act
notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of 	Bridion
(sugammadex) Injection. In March and April 2020, the Company filed patent
- 	22 	-

-- 22 of 54 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies. These
lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications
until June 2023 or until adverse court decisions, if any, whichever may occur earlier. No schedule for the cases has been set by the courts.
Januvia, Janumet, Janumet XR 	— In February 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of
New Jersey, seeking a declaratory judgment of invalidity of a patent owned by the Company covering certain salt and polymorphic forms of sitagliptin that expires
in 2026. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and
additional companies that also indicated an intent to market generic versions of 	Januvia, 	Janumet, and 	Janumet XR 	following expiration of key patent protection in
2022, but prior to the expiration of the later-granted patent owned by the Company covering certain salt and polymorphic forms of sitagliptin that expires in 2026,
and a later granted patent owned by the Company covering the 	Janumet 	formulation which expires in 2028. Par Pharmaceutical dismissed its case in the U.S.
District Court for the District of New Jersey against the Company and will litigate the action in the U.S. District Court for the District of Delaware. The Company
filed a patent infringement lawsuit against Mylan Pharmaceuticals Inc. and Mylan Inc. (Mylan) in the Northern District of West Virginia. The Judicial Panel of
Multidistrict Litigation entered an order transferring the Company’s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated
and consolidated pretrial proceedings with the other cases pending in that district. The U.S. District Court for the District of Delaware has scheduled the lawsuits
for a single 3-day trial on invalidity issues in October 2021. The Court will schedule separate 1-day trials on infringement issues if necessary. In the Company’s
case against Mylan, the U.S. District Court for the Northern District of West Virginia has conditionally scheduled a three-day trial in December 2021 on all issues.
In February 2020, the Company amended its complaint against one defendant, Teva Pharmaceuticals USA, Inc., to add patent infringement claims related to a
patent that expires in 2025 and covers certain processes for manufacturing sitagliptin.
The Company has settled with 	five 	generic companies such that these generic companies can bring their products to the market in November 2026 or
earlier under certain circumstances.
In October 2019, Mylan filed a petition for 	Inter Partes 	Review (IPR) at the United States Patent and Trademark Office (USPTO) seeking invalidity of
some, but not all, of the claims of the 2026 patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims
are not valid. A trial is scheduled for February 2021 and a final decision is expected in May 2021. After institution, 	three 	additional IPR petitions were filed by
Teva Pharmaceuticals USA, Inc., Dr. Reddy’s Laboratories, Inc., and Sun Pharmaceutical Industries Ltd., as well as related entities, which requested joinder with
Mylan’s IPR proceedings. If the challenges are successful, the unchallenged claims of the 2026 patent will remain valid, subject to the Court proceedings described
above.
In Germany, a generic company has sought the revocation of the Supplementary Protection Certificate (SPC) for 	Janumet. If the generic company is
successful, 	Janumet 	could lose market exclusivity in Germany as early as July 2022. It is possible that challenges to the 	Janumet 	SPC could occur in other
European countries.
Other Litigation
There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not
feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss
associated with the resolution of such proceedings is not expected to be material to the Company’s financial condition, results of operations or cash flows either
individually or in the aggregate.
Legal Defense Reserves
Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the
significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the
Company’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and
outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the
associated litigation. The amount of legal defense reserves as of 	June 30, 2020 	and 	December 31, 2019 	of approximately 	$265 million 	and 	$240 million,
respectively, represents the Company’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however,
events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred
by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase
the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.
- 	23 	-

-- 23 of 54 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
9. 	Equity
Three Months Ended June 30,
Common Stock 	Other
Paid-In
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Loss
Treasury Stock 	Non-
controlling
Interests 	Total	($ and shares in millions except per share amounts) 	Shares 	Par Value 	Shares 	Cost
Balance at April 1, 2019 	3,577 	$ 	1,788 	$ 	38,768 	$ 	44,065 	$ 	(5,346) 	994 	$ 	(51,736) 	$ 	131 	$ 	27,670
Net income attributable to Merck & Co., Inc. 	— 	— 	— 	2,670 	— 	— 	— 	— 	2,670
Other comprehensive loss, net of taxes 	— 	— 	— 	— 	(16) 	— 	— 	— 	(16)
Cash dividends declared on common stock ($0.55 per
share) 	— 	— 	— 	(1,440) 	— 	— 	— 	— 	(1,440)
Treasury stock shares purchased 	— 	— 	1,000 	— 	— 	24 	(2,235) 	— 	(1,235)
Share-based compensation plans and other 	— 	— 	(284) 	— 	— 	(8) 	401 	— 	117
Net loss attributable to noncontrolling interests 	— 	— 	— 	— 	— 	— 	— 	(26) 	(26)
Other changes in noncontrolling interests 	— 	— 	— 	— 	— 	— 	— 	(3) 	(3)
Balance at June 30, 2019 	3,577 	$ 	1,788 	$ 	39,484 	$ 	45,295 	$ 	(5,362) 	1,010 	$ 	(53,570) 	$ 	102 	$ 	27,737
Balance at April 1, 2020 	3,577 	$ 	1,788 	$ 	39,697 	$ 	48,272 	$ 	(6,391) 	1,053 	$ 	(57,161) 	$ 	95 	$ 	26,300
Net income attributable to Merck & Co., Inc. 	— 	— 	— 	3,002 	— 	— 	— 	— 	3,002
Other comprehensive loss, net of taxes 	— 	— 	— 	— 	(2) 	— 	— 	— 	(2)
Cash dividends declared on common stock ($0.61 per
share) 	— 	— 	— 	(1,550) 	— 	— 	— 	— 	(1,550)
Share-based compensation plans and other 	— 	— 	(324) 	— 	— 	(5) 	311 	— 	(13)
Net income attributable to noncontrolling interests 	— 	— 	— 	— 	— 	— 	— 	8 	8
Distributions attributable to noncontrolling interests 	— 	— 	— 	— 	— 	— 	— 	(1) 	(1)
Balance at June 30, 2020 	3,577 	$ 	1,788 	$ 	39,373 	$ 	49,724 	$ 	(6,393) 	1,048 	$ 	(56,850) 	$ 	102 	$ 	27,744
Six Months Ended June 30,
Common Stock 	Other
Paid-In
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Loss
Treasury Stock 	Non-
controlling
Interests 	Total	($ and shares in millions except per share amounts) 	Shares 	Par Value 	Shares 	Cost
Balance at January 1, 2019 	3,577 	$ 	1,788 	$ 	38,808 	$ 	42,579 	$ 	(5,545) 	985 	$ 	(50,929) 	$ 	181 	$ 	26,882
Net income attributable to Merck & Co., Inc. 	— 	— 	— 	5,585 	— 	— 	— 	— 	5,585
Other comprehensive income, net of taxes 	— 	— 	— 	— 	183 	— 	— 	— 	183
Cash dividends declared on common stock ($1.10 per
share) 	— 	— 	— 	(2,869) 	— 	— 	— 	— 	(2,869)
Treasury stock shares purchased 	— 	— 	1,000 	— 	— 	38 	(3,325) 	— 	(2,325)
Share-based compensation plans and other 	— 	— 	(324) 	— 	— 	(13) 	684 	— 	360
Net loss attributable to noncontrolling interests 	— 	— 	— 	— 	— 	— 	— 	(79) 	(79)
Balance at June 30, 2019 	3,577 	$ 	1,788 	$ 	39,484 	$ 	45,295 	$ 	(5,362) 	1,010 	$ 	(53,570) 	$ 	102 	$ 	27,737
Balance at January 1, 2020 	3,577 	$ 	1,788 	$ 	39,660 	$ 	46,602 	$ 	(6,193) 	1,038 	$ 	(55,950) 	$ 	94 	$ 	26,001
Net income attributable to Merck & Co., Inc. 	— 	— 	— 	6,221 	— 	— 	— 	— 	6,221
Other comprehensive loss, net of taxes 	— 	— 	— 	— 	(200) 	— 	— 	— 	(200)
Cash dividends declared on common stock ($1.22 per
share) 	— 	— 	— 	(3,099) 	— 	— 	— 	— 	(3,099)
Treasury stock shares purchased 	— 	— 	— 	— 	— 	16 	(1,281) 	— 	(1,281)
Share-based compensation plans and other 	— 	— 	(287) 	— 	— 	(6) 	381 	— 	94
Net income attributable to noncontrolling interests 	— 	— 	— 	— 	— 	— 	— 	8 	8
Balance at June 30, 2020 	3,577 	$ 	1,788 	$ 	39,373 	$ 	49,724 	$ 	(6,393) 	1,048 	$ 	(56,850) 	$ 	102 	$ 	27,744
10. 	Share-Based Compensation Plans
The Company has share-based compensation plans under which the Company grants restricted stock units (RSUs) and performance share units (PSUs)
to certain management level employees. In addition, employees and non-employee directors may be granted options to purchase shares of Company common stock
at the fair market value at the time of grant.
- 	24 	-

-- 24 of 54 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
The following table provides the amounts of share-based compensation cost recorded in the Condensed Consolidated Statement of Income:
Three Months Ended
June 30,
Six Months Ended
June 30,
($ in millions) 	2020 	2019 	2020 	2019
Pretax share-based compensation expense 	$ 	121 	$ 	111 	$ 	229 	$ 	204
Income tax benefit 	(16) 	(15) 	(31) 	(28)
Total share-based compensation expense, net of taxes 	$ 	105 	$ 	96 	$ 	198 	$ 	176
During the first 	six 	months of 	2020, the Company granted 	6 million 	RSUs with a weighted-average grant date fair value of 	$77.74 	per RSU and during
the first 	six 	months of 	2019 	granted 	6 million 	RSUs with a weighted-average grant date fair value of 	$76.31 	per RSU. During the first 	six 	months of 	2020, the
Company granted 	773 thousand 	PSUs with a weighted-average grant date fair value of 	$75.22 	per PSU and during the first 	six 	months of 	2019 	granted 	609
thousand 	PSUs with a weighted-average grant date fair value of 	$90.50 	per PSU.
During the first 	six 	months of 2020, the Company granted 	4 million 	stock options with a weighted-average exercise price of 	$77.67 	per option and
during the first 	six 	months of 2019 granted 	3 million 	stock options with a weighted-average exercise price of 	$80.00 	per option. The weighted-average fair value of
options granted during the first 	six 	months of 2020 and 2019 was 	$9.93 	and 	$10.63 	per option, respectively, and was determined using the following assumptions:
Six Months Ended
June 30,
2020 	2019
Expected dividend yield 	3.1% 	3.2%
Risk-free interest rate 	0.4% 	2.4%
Expected volatility 	22.1% 	18.7%
Expected life (years) 	5.8 	5.9
At 	June 30, 2020, there was 	$908 million 	of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards
which will be recognized over a weighted-average period of 	2.2 years. For segment reporting, share-based compensation costs are unallocated expenses.
11. 	Pension and Other Postretirement Benefit Plans
The Company has defined benefit pension plans covering eligible employees in the United States and in certain of its international subsidiaries. The net
periodic benefit cost of such plans consisted of the following components:
Three Months Ended
June 30,
Six Months Ended
June 30,
2020 	2019 	2020 	2019
($ in millions) 	U.S. 	International 	U.S. 	International 	U.S. 	International 	U.S. 	International
Service cost 	$ 	88 	$ 	74 	$ 	74 	$ 	60 	$ 	175 	$ 	148 	$ 	144 	$ 	120
Interest cost 	109 	33 	113 	44 	217 	68 	228 	89
Expected return on plan assets 	(195) 	(101) 	(205) 	(107) 	(388) 	(205) 	(411) 	(214)
Amortization of unrecognized prior service
credit 	(12) 	(3) 	(12) 	(3) 	(25) 	(6) 	(25) 	(6)
Net loss amortization 	76 	31 	35 	16 	152 	62 	70 	31
Termination benefits 	1 	— 	3 	1 	4 	1 	5 	1
Curtailments 	— 	— 	— 	— 	2 	(1) 	1 	—
Settlements 	9 	2 	— 	— 	9 	2 	— 	—
$ 	76 	$ 	36 	$ 	8 	$ 	11 	$ 	146 	$ 	69 	$ 	12 	$ 	21
The Company now anticipates contributing approximately 	$220 million 	to its U.S. pension plans in 2020, of which 	$170 million 	was contributed in the
first half of the year.
- 	25 	-

-- 25 of 54 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement
benefit plans. The net credit of such plans consisted of the following components:
Three Months Ended
June 30,
Six Months Ended
June 30,
($ in millions) 	2020 	2019 	2020 	2019
Service cost 	$ 	13 	$ 	12 	$ 	26 	$ 	24
Interest cost 	14 	18 	29 	35
Expected return on plan assets 	(19) 	(18) 	(37) 	(36)
Amortization of unrecognized prior service credit 	(22) 	(21) 	(45) 	(43)
Curtailments 	— 	(1) 	(1) 	(1)
$ 	(14) 	$ 	(10) 	$ 	(28) 	$ 	(21)
In connection with restructuring actions (see Note 4), termination charges were recorded on pension plans related to expanded eligibility for certain
employees exiting Merck. Also, in connection with these restructuring actions, curtailments were recorded on pension and other postretirement benefit plans and
settlements were recorded on certain U.S. and international pension plans as reflected in the tables above.
The components of net periodic benefit cost (credit) other than the service cost component are included in 	Other (income) expense, net 	(see Note 12),
with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in 	Restructuring costs 	if the event giving rise to the
termination benefits, curtailment or settlement is related to restructuring actions as noted above.
12. 	Other (Income) Expense, Net
Other (income) expense, net, consisted of:
Three Months Ended
June 30,
Six Months Ended
June 30,
($ in millions) 	2020 	2019 	2020 	2019
Interest income 	$ 	(14) 	$ 	(75) 	$ 	(39) 	$ 	(164)
Interest expense 	209 	233 	421 	442
Exchange losses 	24 	27 	78 	128
Income from investments in equity securities, net 	(1) 	(551) 	(58) 	(603) 	(32)
Net periodic defined benefit plan (credit) cost other than service cost 	(80) 	(140) 	(170) 	(281)
Other, net 	22 	153 	(5) 	234
$ 	(390) 	$ 	140 	$ 	(318) 	$ 	327
(1) 	Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and
losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds are accounted for on a one quarter lag. The
Company estimates that gains of approximately 	$300 million 	will be recognized in the third quarter of 2020 from ownership interests in investment funds.
The decline in interest income in the 	second 	quarter and first 	six 	months of 2020 reflects lower investments and lower interest rates. The lower
exchange losses in the first 	six 	months of 	2020 	reflect losses on forward exchange contracts in 2019 related to the acquisition of Antelliq. The increase in income
from investments in equity securities, net, in both the 	second 	quarter and first 	six 	months of 2020 was driven primarily by the recognition of unrealized gains on
certain investments, most of which relate to Moderna, Inc., as well as NGM Biopharmaceuticals, Inc.
Other, net (as reflected in the table above) in the 	second 	quarter and first 	six 	months of 2019 includes 	$78 million 	and 	$162 million, respectively, of
goodwill impairment charges related to certain businesses in the Healthcare Services segment.
Interest paid for the 	six 	months ended 	June 30, 2020 	and 	2019 	was 	$387 million 	and 	$356 million, respectively.
13. 	Taxes on Income
The effective income tax rates of 	14.5% 	and 	18.9% 	for the 	second 	quarter of 	2020 	and 	2019, respectively, and 	15.3% 	and 	13.0% 	for the first 	six 	months
of 2020 and 2019, respectively, reflect the impacts of acquisition and divestiture-related costs and restructuring costs, partially offset by the beneficial impact of
foreign earnings. In addition, the effective income tax rate for the first 	six 	months of 2019 reflects the favorable impact of a 	$360 million 	net tax benefit related to
the settlement of certain federal income tax matters.
- 	26 	-

-- 26 of 54 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
In the first quarter of 2019, the Internal Revenue Service (IRS) concluded its examinations of Merck’s 2012-2014 U.S. federal income tax returns. As a
result, the Company was required to make a payment of 	$107 million. The Company’s reserves for unrecognized tax benefits for the years under examination
exceeded the adjustments relating to this examination period and therefore the Company recorded a 	$360 million 	net tax benefit in the first 	six 	months of 2019.
This net benefit reflects reductions in reserves for unrecognized tax benefits for tax positions relating to the years that were under examination, partially offset by
additional reserves for tax positions not previously reserved for.
14. 	Earnings Per Share
The calculations of earnings per share are as follows:
Three Months Ended
June 30,
Six Months Ended
June 30,
($ and shares in millions except per share amounts) 	2020 	2019 	2020 	2019
Net income attributable to Merck & Co., Inc. 	$ 	3,002 	$ 	2,670 	$ 	6,221 	$ 	5,585
Average common shares outstanding 	2,527 	2,574 	2,531 	2,579
Common shares issuable 	(1) 	9 	14 	11 	17
Average common shares outstanding assuming dilution 	2,536 	2,588 	2,542 	2,596
Basic earnings per common share attributable to Merck & Co., Inc. common shareholders 	$ 	1.19 	$ 	1.04 	$ 	2.46 	$ 	2.17
Earnings per common share assuming dilution attributable to Merck & Co., Inc. common
shareholders 	$ 	1.18 	$ 	1.03 	$ 	2.45 	$ 	2.15
(1) 	Issuable primarily under share-based compensation plans.
For the 	second 	quarter of 	2020 	and 	2019, 	8 million 	and 	3 million, respectively, and for both the first 	six 	months of 2020 and 2019, 	4 million 	of common
shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect
would have been antidilutive.
15. 	Other Comprehensive Income (Loss)
Changes in 	AOCI 	by component are as follows:
Three Months Ended June 30,
($ in millions) 	Derivatives 	Investments
Employee
Benefit
Plans
Cumulative
Translation
Adjustment
Accumulated Other
Comprehensive
Income (Loss)
Balance April 1, 2019, net of taxes 	$ 	118 	$ 	4 	$ 	(3,541) 	$ 	(1,927) 	$ 	(5,346)
Other comprehensive income (loss) before reclassification
adjustments, pretax 	10 	55 	— 	(25) 	40
Tax 	(2) 	— 	— 	6 	4
Other comprehensive income (loss) before reclassification
adjustments, net of taxes 	8 	55 	— 	(19) 	44
Reclassification adjustments, pretax 	(76) 	(1) 	(11) 	(2) 	14 	(3) 	— 	(73)
Tax 	16 	— 	(3) 	— 	13
Reclassification adjustments, net of taxes 	(60) 	(11) 	11 	— 	(60)
Other comprehensive income (loss), net of taxes 	(52) 	44 	11 	(19) 	(16)
Balance June 30, 2019, net of taxes 	$ 	66 	$ 	48 	$ 	(3,530) 	$ 	(1,946) 	$ 	(5,362)
Balance April 1, 2020, net of taxes 	$ 	135 	$ 	— 	$ 	(4,201) 	$ 	(2,325) 	$ 	(6,391)
Other comprehensive income (loss) before reclassification
adjustments, pretax 	(110) 	— 	(21) 	63 	(68)
Tax 	23 	— 	6 	16 	45
Other comprehensive income (loss) before reclassification
adjustments, net of taxes 	(87) 	— 	(15) 	79 	(23)
Reclassification adjustments, pretax 	(42) 	(1) 	— 	69 	(3) 	— 	27
Tax 	9 	— 	(15) 	— 	(6)
Reclassification adjustments, net of taxes 	(33) 	— 	54 	— 	21
Other comprehensive income (loss), net of taxes 	(120) 	— 	39 	79 	(2)
Balance June 30, 2020, net of taxes 	$ 	15 	$ 	— 	$ 	(4,162) 	$ 	(2,246) 	$ 	(6,393)
- 	27 	-

-- 27 of 54 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
Six Months Ended June 30,
($ in millions) 	Derivatives 	Investments
Employee
Benefit
Plans
Cumulative
Translation
Adjustment
Accumulated Other
Comprehensive
Income (Loss)
Balance January 1, 2019, net of taxes 	$ 	166 	$ 	(78) 	$ 	(3,556) 	$ 	(2,077) 	$ 	(5,545)
Other comprehensive income (loss) before reclassification
adjustments, pretax 	(3) 	131 	(1) 	131 	258
Tax 	1 	— 	6 	— 	7
Other comprehensive income (loss) before reclassification
adjustments, net of taxes 	(2) 	131 	5 	131 	265
Reclassification adjustments, pretax 	(124) 	(1) 	(5) 	(2) 	28 	(3) 	— 	(101)
Tax 	26 	— 	(7) 	— 	19
Reclassification adjustments, net of taxes 	(98) 	(5) 	21 	— 	(82)
Other comprehensive income (loss), net of taxes 	(100) 	126 	26 	131 	183
Balance June 30, 2019, net of taxes 	$ 	66 	$ 	48 	$ 	(3,530) 	$ 	(1,946) 	$ 	(5,362)
Balance January 1, 2020, net of taxes 	$ 	31 	$ 	18 	$ 	(4,261) 	$ 	(1,981) 	$ 	(6,193)
Other comprehensive income (loss) before reclassification
adjustments, pretax 	68 	3 	(21) 	(270) 	(220)
Tax 	(14) 	— 	11 	5 	2
Other comprehensive income (loss) before reclassification
adjustments, net of taxes 	54 	3 	(10) 	(265) 	(218)
Reclassification adjustments, pretax 	(89) 	(1) 	(21) 	(2) 	138 	(3) 	— 	28
Tax 	19 	— 	(29) 	— 	(10)
Reclassification adjustments, net of taxes 	(70) 	(21) 	109 	— 	18
Other comprehensive income (loss), net of taxes 	(16) 	(18) 	99 	(265) 	(200)
Balance June 30, 2020, net of taxes 	$ 	15 	$ 	— 	$ 	(4,162) 	$ 	(2,246) 	$ 	(6,393)
(1) 	Relates to foreign currency cash flow hedges that were reclassified from 	AOCI 	to 	Sales.
(2) 	Represents net realized (gains) losses on the sales of available-for-sale debt securities that were reclassified from 	AOCI 	to 	Other (income) expense, net.
(3) 	Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 11).
16. 	Segment Reporting
The Company’s operations are principally managed on a products basis and include 	three 	operating segments, which are the Pharmaceutical, Animal
Health and Healthcare Services segments. The Pharmaceutical and Animal Health segments are the only reportable segments.
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic
and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products
primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy
benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at
physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large
component of pediatric and adolescent vaccine sales are made to the U.S. Centers for Disease Control and Prevention Vaccines for Children program, which is
funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.
The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as
health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company
also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians,
distributors and animal producers.
The Healthcare Services segment provided services and solutions that focus on engagement, health analytics and clinical services to improve the value
of care delivered to patients. The Company has been in the process of divesting the businesses in the Healthcare Services segment. The remaining businesses were
divested during the first quarter of 2020.
- 	28 	-

-- 28 of 54 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
Sales of the Company’s products were as follows:
Three Months Ended June 30, 	Six Months Ended June 30,
2020 	2019 	2020 	2019
($ in millions) 	U.S. 	Int’l 	Total 	U.S. 	Int’l 	Total 	U.S. 	Int’l 	Total 	U.S. 	Int’l 	Total
Pharmaceutical:
Oncology
Keytruda 	$ 	2,043 	$ 	1,345 	$ 	3,388 	$ 	1,498 	$ 	1,136 	$ 	2,634 	$ 	3,949 	$ 	2,722 	$ 	6,672 	$ 	2,782 	$ 	2,121 	$ 	4,903
Alliance revenue - Lynparza 	(1)
105 	73 	178 	66 	45 	111 	190 	133 	323 	116 	74 	190
Alliance revenue - Lenvima 	(1)
98 	53 	151 	54 	43 	97 	188 	91 	279 	104 	67 	171
Emend 	6 	27 	33 	67 	54 	121 	11 	65 	76 	130 	107 	237
Vaccines
Gardasil/Gardasil 	9 	168 	488 	656 	456 	430 	886 	629 	1,124 	1,753 	818 	906 	1,724
ProQuad/M-M-R 	II/Varivax 	263 	115 	378 	500 	174 	675 	596 	217 	813 	843 	328 	1,171
RotaTeq 	100 	68 	168 	104 	68 	172 	241 	150 	391 	258 	125 	383
Pneumovax 	23 	21 	96 	117 	123 	47 	170 	203 	170 	373 	248 	107 	355
Vaqta 	17 	11 	28 	38 	20 	58 	47 	41 	88 	67 	39 	105
Hospital Acute Care
Bridion 	107 	117 	224 	129 	149 	278 	250 	274 	524 	248 	285 	533
Noxafil 	6 	67 	73 	100 	93 	193 	14 	154 	168 	191 	192 	383
Prevymis 	28 	35 	63 	19 	18 	38 	55 	68 	123 	37 	33 	70
Primaxin 	1 	63 	64 	— 	70 	71 	1 	114 	115 	1 	129 	130
Invanz 	— 	43 	43 	18 	60 	78 	6 	102 	108 	31 	118 	150
Cancidas 	(2) 	45 	43 	3 	64 	67 	1 	98 	98 	4 	125 	129
Cubicin 	10 	21 	32 	22 	45 	67 	25 	53 	78 	64 	91 	155
Zerbaxa 	17 	15 	32 	13 	14 	27 	37 	32 	69 	25 	28 	53
Immunology
Simponi 	— 	191 	191 	— 	214 	214 	— 	406 	406 	— 	422 	422
Remicade 	— 	73 	73 	— 	98 	98 	— 	160 	160 	— 	221 	221
Neuroscience
Belsomra 	22 	61 	84 	21 	55 	76 	49 	114 	163 	45 	98 	143
Virology
Isentress/Isentress 	HD 	76 	120 	196 	94 	153 	247 	151 	290 	441 	202 	300 	502
Zepatier 	15 	24 	39 	39 	68 	108 	33 	62 	94 	72 	149 	221
Cardiovascular
Zetia 	(1) 	138 	137 	6 	150 	156 	(4) 	285 	282 	6 	290 	296
Vytorin 	2 	37 	39 	3 	73 	76 	5 	86 	92 	6 	167 	174
Atozet 	— 	115 	115 	— 	92 	92 	— 	238 	238 	— 	186 	186
Alliance revenue - Adempas 	(2)
73 	6 	79 	49 	2 	51 	122 	11 	133 	89 	5 	94
Adempas 	— 	57 	57 	— 	53 	53 	— 	113 	113 	— 	100 	100
Diabetes
Januvia 	413 	441 	854 	471 	437 	908 	768 	860 	1,628 	855 	877 	1,732
Janumet 	143 	348 	490 	166 	366 	533 	256 	737 	993 	333 	730 	1,063
Women’s Health
Implanon/Nexplanon 	87 	44 	132 	136 	48 	183 	237 	90 	326 	285 	98 	382
NuvaRing 	35 	28 	63 	206 	34 	240 	61 	65 	126 	391 	68 	459
Diversified Brands
Singulair 	4 	96 	100 	8 	153 	160 	9 	246 	255 	13 	338 	352
Cozaar/Hyzaar 	4 	94 	98 	6 	103 	109 	12 	189 	200 	10 	202 	213
Arcoxia 	— 	65 	65 	— 	75 	75 	— 	135 	135 	— 	149 	149
Nasonex 	4 	45 	49 	(1) 	73 	72 	10 	110 	120 	(2) 	170 	168
Follistim AQ 	20 	24 	44 	24 	39 	63 	40 	45 	85 	53 	67 	121
Other pharmaceutical 	(3) 	385 	720 	1,103 	369 	837 	1,203 	792 	1,500 	2,293 	697 	1,589 	2,283
Total Pharmaceutical segment sales 	4,270 	5,409 	9,679 	4,807 	5,653 	10,460 	8,984 	11,350 	20,334 	9,022 	11,101 	20,123
Animal Health:

-- 29 of 54 --

Livestock 	122 	526 	648 	145 	526 	671 	284 	1,102 	1,386 	261 	1,021 	1,282
Companion Animals 	220 	233 	453 	190 	263 	453 	442 	486 	928 	367 	500 	867
Total Animal Health segment sales 	342 	759 	1,101 	335 	789 	1,124 	726 	1,588 	2,314 	628 	1,521 	2,149
Other segment sales 	(4) 	— 	— 	— 	47 	— 	48 	23 	— 	23 	86 	— 	87
Total segment sales 	4,612 	6,168 	10,780 	5,189 	6,442 	11,632 	9,733 	12,938 	22,671 	9,736 	12,622 	22,359
Other 	(5) 	22 	70 	92 	4 	125 	128 	38 	220 	258 	12 	206 	216
$ 	4,634 	$ 	6,238 	$ 	10,872 	$ 	5,193 	$ 	6,567 	$ 	11,760 	$ 	9,771 	$ 	13,158 	$ 	22,929 	$ 	9,748 	$ 	12,828 	$ 	22,575
U.S. plus international may not equal total due to rounding.
(1) 	Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).
(2) 	Alliance revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3).
(3) 	Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.
(4) 	Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were divested as of March 31, 2020.
(5) 	Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales. Other in the first 	six 	months of 2020 and 2019 also includes approximately 	$85
million 	and 	$15 million, respectively, related to the sale of the marketing rights for certain products.
- 	29 	-

-- 30 of 54 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted
customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements
with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan
participant. These discounts, in the aggregate, reduced U.S. sales by 	$3.0 billion 	and 	$2.9 billion 	for the three months ended 	June 30, 2020 	and 	2019, respectively,
and 	$6.2 billion 	and 	$5.5 billion 	for the 	six 	months ended 	June 30, 2020 	and 	2019, respectively.
Consolidated sales by geographic area where derived are as follows:
Three Months Ended
June 30,
Six Months Ended
June 30,
($ in millions) 	2020 	2019 	2020 	2019
United States 	$ 	4,634 	$ 	5,193 	$ 	9,771 	$ 	9,748
Europe, Middle East and Africa 	3,071 	3,163 	6,605 	6,265
China 	834 	763 	1,699 	1,509
Japan 	867 	921 	1,678 	1,720
Asia Pacific (other than China and Japan) 	666 	716 	1,394 	1,461
Latin America 	510 	658 	1,066 	1,219
Other 	290 	346 	716 	653
$ 	10,872 	$ 	11,760 	$ 	22,929 	$ 	22,575
A reconciliation of segment profits to 	Income before taxes 	is as follows:
Three Months Ended
June 30,
Six Months Ended
June 30,
($ in millions) 	2020 	2019 	2020 	2019
Segment profits:
Pharmaceutical segment 	$ 	6,560 	$ 	7,115 	$ 	14,036 	$ 	13,690
Animal Health segment 	407 	405 	885 	820
Other segment 	— 	(2) 	2 	—
Total segment profits 	6,967 	7,518 	14,923 	14,510
Other profits 	61 	94 	200 	124
Unallocated:
Interest income 	14 	75 	39 	164
Interest expense 	(209) 	(233) 	(421) 	(442)
Depreciation and amortization 	(390) 	(427) 	(772) 	(786)
Research and development 	(1,994) 	(2,093) 	(4,092) 	(3,935)
Amortization of purchase accounting adjustments 	(299) 	(378) 	(594) 	(775)
Restructuring costs 	(83) 	(59) 	(155) 	(212)
Other unallocated, net 	(548) 	(1,238) 	(1,771) 	(2,322)
$ 	3,519 	$ 	3,259 	$ 	7,357 	$ 	6,326
Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly
incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative
expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker,
Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck
Research Laboratories, the Company’s research and development division that focuses on human health-related activities, or general and administrative expenses,
nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed
assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the
amortization of purchase accounting adjustments are not allocated to segments.
Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing sales.
Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains
or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other
miscellaneous income or expense items.
- 	30 	-

-- 31 of 54 --

Notes to Condensed Consolidated Financial Statements (unaudited) 	(continued)
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Planned Spin-Off of Women’s Health, Legacy Brands and Biosimilars into New Company
In February 2020, Merck announced its intention to spin-off products from its women’s health, legacy brands and biosimilars businesses into a new,
independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon’s publicly traded stock to Company shareholders. The
distribution is expected to qualify as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The legacy brands included in the
transaction consist of dermatology, non-opioid pain, respiratory, and select cardiovascular products including 	Zetia 	(ezetimibe) and 	Vytorin 	(ezetimibe and
simvastatin), as well as the rest of Merck’s diversified brands franchise. Merck’s existing research pipeline programs will continue to be owned and developed
within Merck as planned. Organon will have development capabilities initially focused on late-stage development and life-cycle management and is expected over
time to develop research capabilities in selected therapeutic areas. The spin-off is expected to be completed in the first half of 2021, subject to market and certain
other conditions. Subsequent to the spin-off, the historical results of the women’s health, legacy brands and biosimilars businesses will be reflected as discontinued
operations in the Company’s consolidated financial statements.
Recent Developments
Business Developments
Below is a summary of significant business development activity in the first 	six 	months of 	2020. See Note 2 to the condensed consolidated financial
statements for additional information.
In July 2020, Merck acquired the U.S. rights to Sentinel Flavor Tabs and Sentinel Spectrum Chews from Virbac Corporation for approximately 	$400
million. Sentinel products provide protection against common parasites in dogs.
Also, in July 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback Bio), a closely held biotechnology company, closed a collaboration
agreement to develop MK-4482 (formerly known as EIDD-2801), an orally available antiviral candidate currently in clinical development for the treatment of
patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize MK-4482 and related molecules. Under the terms of the
agreement, Ridgeback Bio received an upfront payment and also is eligible to receive future contingent payments dependent upon the achievement of certain
developmental and regulatory approval milestones, as well as a share of the net profits of MK-4482 and related molecules, if approved.
In June 2020, Merck acquired privately held Themis Bioscience GmbH (Themis), a company focused on vaccines and immune-modulation therapies
for infectious diseases and cancer for 	$366 million 	in cash. Merck may make additional contingent payments dependent upon the achievement of certain
developmental, regulatory approval and commercial milestones. The acquisition builds upon an ongoing collaboration between the two companies to develop
vaccine candidates using the measles virus vector platform and is expected to accelerate the development of Themis’ COVID-19 vaccine candidate (V591).
In May 2020, Merck and the International AIDS Vaccine Initiative, Inc. (IAVI), a nonprofit scientific research organization dedicated to addressing
urgent, unmet global health challenges, announced a new collaboration to develop V590, an investigational vaccine against SARS-CoV-2 being studied for the
prevention of COVID-19. Under the terms of the agreement, Merck made an upfront payment of 	$6.5 million 	and may make additional contingent payments
dependent upon the achievement of certain sales-based milestones, as well as royalties.
In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and
development for the treatment of patients with cancer and other diseases, for $2.7 billion. ArQule’s lead investigational candidate, MK-1026 (formerly known as
ARQ 531), is a novel, oral Bruton’s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies.
Coronavirus Disease 2019 (COVID-19) Update
Overall, in response to the COVID-19 pandemic, Merck is focused on protecting the safety of its employees, ensuring that its supply of medicines and
vaccines reaches its patients, contributing its scientific expertise to the development of vaccine and antiviral approaches, and supporting health care providers and
Merck’s communities. Although COVID-19-related disruptions to patients’ ability to access health care providers negatively affected second quarter results, Merck
remains confident in the fundamental underlying demand for its products and its prospects for long-term growth.
In the 	second 	quarter of 2020, the negative impact of the COVID-19 pandemic to Merck’s sales was estimated to be $1.6 billion, including
approximately $1.5 billion for Pharmaceutical revenue and approximately $100 million for Animal Health revenue. The impact to sales in the first quarter of 2020
was immaterial. For the full-year 2020, Merck expects an unfavorable impact to sales of approximately $1.95 billion (excluding the impact of foreign exchange)
due to the COVID-19 pandemic, comprised of approximately $1.8 billion for Pharmaceutical revenue and approximately $150 million for Animal Health revenue.
These estimates include the impacts for the first half of the year.
- 	31 	-

-- 32 of 54 --

Roughly two-thirds of Merck’s Pharmaceutical revenue is comprised of physician-administered products, which, despite strong underlying demand,
were affected by social distancing measures, fewer well visits and delays in elective surgeries due to the COVID-19 pandemic. These impacts, as well as the
prioritization of COVID-19 patients at health care providers, have resulted in reduced administration of many of the Company’s human health products, in
particular for its vaccines as well as for 	Keytruda 	(pembrolizumab) and 	Implanon/Nexplanon 	(etonogestrel implant). The Company anticipates reduced demand for
its physician-administered products while pandemic-related access measures remain in place. In addition, declines in medical visits and elective surgeries also
negatively affected the demand for certain products, including 	Bridion 	(sugammadex) Injection. In Merck’s Animal Health business, reduced veterinary visits and
lower demand for protein and milk due to restaurant and school closures have negatively affected sales.
While the Company expects to rely on governmental authorities to determine when operations can return to normal, and is cognizant that the duration,
spread and severity of the outbreak will be critical determinants for the purposes of the full-year estimates provided above, Merck has assumed that the majority of
the negative impact occurred in the second quarter of 2020, with a gradual recovery having commenced in the second quarter and extending through the third
quarter, with a return to normal operating levels in the fourth quarter of 2020.
Operating expenses were positively affected in the 	second 	quarter and first 	six 	months of 2020 by approximately $325 million and $425 million,
respectively, primarily driven by lower promotional and selling costs, as well as lower research and development expenses due to the COVID-19 pandemic. For the
full-year 2020, Merck continues to expect a net favorable impact to operating expenses of approximately $400 million including both the favorable impact of lower
spending, largely reflected in the first half of 2020, partially offset by anticipated spending on recently initiated COVID-19-related vaccine and antiviral research
programs.
Pricing
Global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide. In the United States,
pricing pressure continues on many of the Company’s products. Changes to the U.S. health care system as part of health care reform, as well as increased
purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several
international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company’s revenue performance in
the first 	six 	months of 	2020 	was negatively affected by other cost-reduction measures taken by governments and other third-parties to lower health care costs. The
Company anticipates all of these actions and additional actions in the future will continue to negatively affect revenue performance.
Operating Results
Sales
Three Months Ended
June 30,
% Change
Excluding
Foreign
Exchange
Six Months Ended
June 30,
% Change
Excluding
Foreign
Exchange	($ in millions) 	2020 	2019 	% Change 	2020 	2019 	% Change
United States 	$ 	4,634 	$ 	5,193 	(11)% 	(11)% 	$ 	9,771 	$ 	9,748 	—% 	—%
International 	6,238 	6,567 	(5)% 	— 	% 	13,158 	12,828 	3% 	6%
Total 	$ 	10,872 	$ 	11,760 	(8)% 	(5)% 	$ 	22,929 	$ 	22,575 	2% 	4%
U.S. plus international may not equal total due to rounding.
Worldwide sales were 	$10.9 billion 	for the 	second 	quarter of 	2020, a decline of 	8% 	compared with the 	second 	quarter of 	2019, reflecting an unfavorable
impact from the COVID-19 pandemic as discussed above. The sales decline reflects lower sales of vaccines, including human papillomavirus (HPV) vaccines
Gardasil 	(Human 	Papillomavirus 	Quadrivalent 	[Types 	6,11,16 	and 	18] 	Vaccine, 	Recombinant)/Gardasil 	9 	(Human 	Papillomavirus 	9-valent 	Vaccine,
Recombinant) and lower sales of pediatric vaccines 	ProQuad 	(Measles, Mumps, Rubella and Varicella Virus Vaccine Live), 	M-M-R 	II (Measles, Mumps and
Rubella Virus Vaccine Live) and 	Varivax 	(Varicella Virus Vaccine Live). The sales decline was also attributable to the ongoing effects of generic competition for
women’s health product 	NuvaRing 	(etonogestrel/ethinyl estradiol vaginal ring), hospital acute care products 	Noxafil 	(posaconazole) and 	Cubicin 	(daptomycin for
injection), oncology products 	Emend 	(aprepitant)/ 	Emend 	(fosaprepitant dimeglumine) for Injection, cardiovascular products 	Zetia 	(ezetimibe) and 	Vytorin
(ezetimibe/simvastatin), as well as products within the diversified brands franchise. The diversified brands franchise includes certain products that are approaching
the expiration of their marketing exclusivity or that are no longer protected by patents in developed markets. Lower sales of diabetes products 	Januvia 	(sitagliptin)
and 	Janumet 	(sitagliptin/metformin HCl) and virology product 	Zepatier 	(elbasvir and grazoprevir) also contributed to the revenue decline in the quarter. The sales
decline was partially offset by higher sales in the oncology franchise reflecting strong growth of 	Keytruda, as well as increased alliance revenue from Lynparza
(olaparib) and Lenvima (lenvatinib).
- 	32 	-

-- 33 of 54 --

Global sales were 	$22.9 billion 	for the first 	six 	months of 2020, growth of 	2% 	compared with the same period of 2019. Sales growth was largely due to
higher sales in the oncology franchise and higher sales of animal health products, partially offset by ongoing generic competition for certain brands, and an
unfavorable impact from the COVID-19 pandemic that resulted in lower demand for certain products.
See Note 16 to the condensed consolidated financial statements for details on sales of the Company’s products. A discussion of performance for select
products in the franchises follows.
Pharmaceutical Segment
Oncology
Three Months Ended
June 30,
% Change
Excluding
Foreign
Exchange
Six Months Ended
June 30,
% Change
Excluding
Foreign
Exchange	($ in millions) 	2020 	2019 	% Change 	2020 	2019 	% Change
Keytruda 	$ 	3,388 	$ 	2,634 	29 	% 	31 	% 	$ 	6,672 	$ 	4,903 	36 	% 	38 	%
Alliance Revenue - Lynparza 	(1) 	178 	111 	61 	% 	62 	% 	323 	190 	70 	% 	72 	%
Alliance Revenue - Lenvima 	(1) 	151 	97 	57 	% 	57 	% 	279 	171 	63 	% 	64 	%
Emend 	33 	121 	(72)% 	(71)% 	76 	237 	(68)% 	(67)%
(1) 	Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3 to the condensed consolidated financial statements).
Keytruda 	is an anti-PD-1 (programmed death receptor-1) therapy that has been approved as monotherapy for the treatment of certain patients with
cervical cancer, classical Hodgkin lymphoma (cHL), cutaneous squamous cell carcinoma (cSCC), esophageal cancer, gastric or gastroesophageal junction
adenocarcinoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), non-small-cell lung cancer (NSCLC), small-cell lung cancer
(SCLC), melanoma, Merkel cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient cancer, primary mediastinal large B-cell
lymphoma (PMBCL), and urothelial carcinoma. 	Keytruda 	is also approved for the treatment of certain patients in combination with chemotherapy for metastatic
squamous and nonsquamous NSCLC, in combination with chemotherapy for HNSCC, in combination with axitinib for renal cell carcinoma (RCC), and in
combination with Lenvima for endometrial carcinoma. The 	Keytruda 	clinical development program includes studies across a broad range of cancer types (see
“Research and Development” below).
In January 2020, the U.S. Food and Drug Administration (FDA) approved 	Keytruda 	as monotherapy for the treatment of certain patients with Bacillus
Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) based on the results of the KEYNOTE-057 trial.
In April 2020, the FDA granted accelerated approval for an additional recommended dosage of 400 mg every six weeks (Q6W) for 	Keytruda 	across all
adult indications, 	including monotherapy and combination therapy. This new dosage option will be available in addition to the current dose of 200 mg every three
weeks (Q3W).
In June 2020, the FDA granted accelerated approval for 	Keytruda 	as monotherapy for the treatment of adult and pediatric patients with unresectable or
metastatic tumor mutational burden-high (TMB-H) (≥10 mutations/megabase) solid tumors, as determined by an FDA-approved test, that have progressed
following prior treatment and who have no satisfactory alternative treatment options based in part on the results of the KEYNOTE-158 trial.
Also in June 2020, the FDA approved 	Keytruda 	as monotherapy both for the treatment of patients with recurrent or metastatic cSCC that is not curable
by surgery or radiation based on data from the Phase 2 KEYNOTE-629 trial and 	for the first-line treatment of patients with unresectable or metastatic MSI-H or
mismatch repair deficient colorectal cancer based on results from the Phase 3 KEYNOTE-177 trial.
In addition, in June 2020, 	Keytruda 	was approved by the National Medical Products Administration (NMPA) in China as monotherapy for the second-
line treatment of patients with locally advanced or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 (Combined Positive Score [CPS]
≥10). This indication was granted based on the Phase 3 KEYNOTE-181 trial, including data from an extension of the global study in Chinese patients.
Global sales of 	Keytruda 	grew 	29% 	and 	36% 	in the 	second 	quarter and first 	six 	months of 	2020, respectively. Sales growth in both periods was driven
by higher demand as the Company continues to launch 	Keytruda 	with multiple new indications globally, although the COVID-19 pandemic had a dampening effect
on growing demand. Sales in the United States continue to build across the multiple approved indications, in particular for the treatment of NSCLC as
monotherapy, and in combination with chemotherapy for both nonsquamous and squamous metastatic NSCLC, along with uptake in the adjuvant melanoma and
RCC indications. Other indications contributing to U.S. sales growth include HNSCC, bladder cancer, melanoma, and MSI-H cancer. 	Keytruda 	sales growth in
international markets was driven by continued uptake in approved indications, particularly in the European Union (EU).
- 	33 	-

-- 34 of 54 --

Pursuant to a re-pricing rule, the Japanese government reduced the price of 	Keytruda 	by 17.5% effective February 2020. Additionally, 	Keytruda 	was
subject to another price reduction of 20.9% in April 2020 under a provision of the Japanese pricing rules.
Lynparza, an oral poly (ADP-ribose) polymerase (PARP) inhibitor being developed as part of a collaboration with AstraZeneca PLC (AstraZeneca) (see
Note 3 to the condensed consolidated financial statements), is approved for the treatment of certain types of advanced ovarian, breast, pancreatic and prostate
cancers. Alliance revenue related to Lynparza increased 	61% 	and 	70% 	in the 	second 	quarter and first 	six 	months of 	2020, respectively. Sales growth in both periods
was largely driven by continued uptake across the multiple approved indications in the United States and in the EU. In May 2020, the FDA approved Lynparza in
combination with bevacizumab as a first-line maintenance treatment of certain adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal
cancer who are in complete or partial response to first-line platinum-based chemotherapy based on the results from the Phase 3 PAOLA-1 trial. Also in May 2020,
the FDA approved Lynparza for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair
(HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone
based on positive results from the Phase 3 PROfound trial. In July 2020, Lynparza was approved in the EU as a monotherapy for the maintenance treatment of
adult patients with germline 	BRCA1/2 mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of
platinum treatment within a first-line chemotherapy regimen based on the results from the Phase 3 POLO trial.
Lenvima, an oral receptor tyrosine kinase inhibitor being developed as part of a collaboration with Eisai Co., Ltd. (Eisai) (see Note 3 to the condensed
consolidated financial statements), is approved for the treatment of certain types of thyroid cancer, HCC, in combination with everolimus for certain patients with
RCC, and in combination with 	Keytruda 	for the treatment of certain patients with endometrial carcinoma. Alliance revenue related to Lenvima grew 	57% 	and 	63%
in the 	second 	quarter and first 	six 	months of 	2020, respectively. Sales growth in both periods was primarily due to higher demand in the United States, the EU and
China.
Global sales of 	Emend, for the prevention of chemotherapy-induced nausea and vomiting, declined 	72% 	and 	68% 	in the 	second 	quarter and first 	six
months of 	2020, respectively. The sales declines were primarily driven by lower demand and pricing in the United States due to generic competition, including
recent generic competition for 	Emend 	for Injection following U.S. patent expiry in September 2019. Also contributing to the sales declines in the 	second 	quarter
and first 	six 	months of 	2020 	was lower demand in the EU as a result of generic competition for the oral formulation of 	Emend 	following loss of market exclusivity
in May of 2019. U.S. market exclusivity for the oral formulation of 	Emend 	previously expired in 2015. 	Emend 	for Injection will lose market exclusivity in major
European markets in August 2020. The Company anticipates that sales of 	Emend 	for Injection in these markets will decline significantly thereafter.
In April 2020, the FDA approved Koselugo (selumetinib) for the treatment of pediatric patients two years of age and older with neurofibromatosis type
1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). The FDA approval is based on positive results from the National Cancer Institute (NCI)
Cancer Therapy Evaluation Program (CTEP)-sponsored Phase 2 SPRINT Stratum 1 trial coordinated by the NCI’s Center for Cancer Research, Pediatric Oncology
Branch. This is the first regulatory approval of a medicine for the treatment of NF1 PN, a rare and debilitating genetic condition. Koselugo is being jointly
developed and commercialized with AstraZeneca globally (see Note 3 to the condensed consolidated financial statements).
Vaccines
Three Months Ended
June 30,
% Change
Excluding
Foreign
Exchange
Six Months Ended
June 30,
% Change
Excluding
Foreign
Exchange	($ in millions) 	2020 	2019 	% Change 	2020 	2019 	% Change
Gardasil/Gardasil 9 	$ 	656 	$ 	886 	(26)% 	(24)% 	$ 	1,753 	$ 	1,724 	2 	% 	4 	%
ProQuad 	133 	204 	(35)% 	(35)% 	290 	356 	(19)% 	(18)%
M-M-R 	II 	72 	199 	(64)% 	(64)% 	172 	322 	(47)% 	(46)%
Varivax 	173 	271 	(36)% 	(35)% 	352 	492 	(29)% 	(28)%
Pneumovax 	23 	117 	170 	(31)% 	(29)% 	373 	355 	5 	% 	7 	%
Worldwide sales of 	Gardasil/Gardasil 	9, vaccines to help prevent certain cancers and other diseases caused by certain types of HPV, declined 	26% 	in
the 	second 	quarter of 	2020 	primarily due to lower demand in the United States and Hong Kong, SAR, PRC attributable to the COVID-19 pandemic, partially offset
by higher demand in China. Worldwide sales of 	Gardasil/Gardasil 	9 grew 	2% 	in the first 	six 	months of 2020 driven by higher demand in China and in the EU,
partially offset by the unfavorable effects of the COVID-19 pandemic, particularly in the United States and Hong Kong, SAR, PRC.
- 	34 	-

-- 35 of 54 --

In June 2020, the FDA approved an expanded indication for 	Gardasil 	9 for the prevention of oropharyngeal and other head and neck cancers caused by
HPV Types 16, 18, 31, 33, 45, 52, and 58. The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness
in preventing HPV-related anogenital disease.
In July 2020, 	Silgard 	9 aqueous suspension for intramuscular injection syringes (recombinant adsorbed 9-valent Human Papillomavirus virus-like
particles vaccine) were approved for use in women and girls by the Ministry of Health, Labor and Welfare in Japan.
Global sales of 	ProQuad, a pediatric combination vaccine to help protect against measles, mumps, rubella and varicella, declined 	35% 	and 	19% 	in the
second 	quarter and first 	six 	months of 	2020, respectively, primarily due to lower demand in the United States resulting from the COVID-19 pandemic.
Worldwide sales of 	M‑M‑R 	II, a vaccine to help protect against measles, mumps and rubella, declined 	64% 	and 	47% 	in the 	second 	quarter and first 	six
months of 	2020, respectively, primarily driven by lower demand in the United States resulting from fewer measles outbreaks in 2020, coupled with the unfavorable
impact of the COVID-19 pandemic. Private sector buy-in during the second quarter of 2019 also contributed to the U.S. 	M-M-R 	II sales declines in the 	second
quarter and first 	six 	months of 	2020. Additionally, the sales decline in the first 	six 	months of 	2020 	reflects lower demand in Brazil.
Global sales of 	Varivax, a vaccine to help prevent chickenpox (varicella), declined 	36% 	and 	29% 	in the 	second 	quarter and first 	six 	months of 	2020,
respectively. The sales declines reflect lower government tenders in Brazil, as well as lower demand in the United States resulting from the COVID-19 pandemic.
Worldwide sales of 	Pneumovax 	23 (pneumococcal vaccine polyvalent), a vaccine to help prevent pneumococcal disease, declined 	31% 	in the 	second
quarter of 	2020 	primarily due to lower demand in the United States related to the COVID-19 pandemic, partially offset by higher volumes in the EU attributable in
part to increased demand for pneumococcal vaccination during the COVID-19 pandemic. Global sales of 	Pneumovax 	23 grew 	5% 	in first 	six 	months of 	2020
largely due to higher demand in the EU, partially offset by lower demand in the United States and the timing of shipments in China.
Hospital Acute Care
Three Months Ended
June 30,
% Change
Excluding
Foreign
Exchange
Six Months Ended
June 30,
% Change
Excluding
Foreign
Exchange	($ in millions) 	2020 	2019 	% Change 	2020 	2019 	% Change
Bridion 	$ 	224 	$ 	278 	(19)% 	(18)% 	$ 	524 	$ 	533 	(2)% 	— 	%
Noxafil 	73 	193 	(62)% 	(60)% 	168 	383 	(56)% 	(55)%
Prevymis 	63 	38 	66 	% 	67 	% 	123 	70 	76 	% 	78 	%
Cubicin 	32 	67 	(53)% 	(51)% 	78 	155 	(50)% 	(48)%
Worldwide sales of 	Bridion, for the reversal of two types of neuromuscular blocking agents used during surgery, declined 	19% 	in the 	second 	quarter of
2020 	primarily attributable to lower demand resulting from fewer elective surgeries due to the COVID-19 pandemic. Excluding the impact of foreign exchange,
global sales of 	Bridion 	in the first 	six 	months of 2020 were flat as higher demand in the first quarter was offset by lower demand in the second quarter resulting
from the COVID-19 pandemic.
Global sales of 	Noxafil, for the prevention of invasive fungal infections, declined 	62% 	and 	56% 	in the 	second 	quarter and first 	six 	months of 	2020,
respectively, primarily due to generic competition in the United States and in the EU. The patents that provided U.S. market exclusivity for certain forms of 	Noxafil
representing the majority of U.S. 	Noxafil 	sales expired in July 2019. Additionally, the patent for 	Noxafil 	expired in a number of major European markets in
December 2019. Accordingly, the Company is experiencing volume and pricing declines in 	Noxafil 	sales in these markets as a result of generic competition and
expects the declines to continue.
Worldwide sales of 	Prevymis 	(letermovir), a medicine for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in adult CMV-
seropositive recipients of an allogenic hematopoietic stem cell transplant, grew 	66% 	and 	76% 	in the 	second 	quarter and first 	six 	months of 	2020, respectively, due
to continued uptake since launch in the EU and in the United States.
Global sales of 	Cubicin, an I.V. antibiotic for complicated skin and skin structure infections or bacteremia when caused by designated susceptible
organisms, declined 	53% 	and 	50% 	in the 	second 	quarter and first 	six 	months of 	2020, respectively, due in part to ongoing generic competition in the United States
and in the EU.
In June 2020, the FDA approved a supplemental New Drug Application (sNDA) for 	Recarbrio 	(imipenem, cilastatin, and relebactam) for the treatment
of patients 18 years of age and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by certain
susceptible Gram-negative microorganisms.
- 	35 	-

-- 36 of 54 --

Immunology
Three Months Ended
June 30,
% Change
Excluding
Foreign
Exchange
Six Months Ended
June 30,
% Change
Excluding
Foreign
Exchange	($ in millions) 	2020 	2019 	% Change 	2020 	2019 	% Change
Simponi 	$ 	191 	$ 	214 	(11)% 	(8)% 	$ 	406 	$ 	422 	(4)% 	(1)%
Remicade 	73 	98 	(26)% 	(25)% 	160 	221 	(28)% 	(26)%
Sales of 	Simponi 	(golimumab), a once-monthly subcutaneous treatment for certain inflammatory diseases (marketed by the Company in Europe, Russia
and Turkey), declined 	11% 	and 	4% 	in the 	second 	quarter and first 	six 	month of 	2020, respectively, primarily driven by lower demand in the EU due to the uptake
of biosimilars for a competing product. Higher volumes in Russia partially offset the decline in the first 	six 	months of 2020.
Sales of 	Remicade 	(infliximab), 	a treatment for inflammatory diseases (marketed by the Company in Europe, Russia and Turkey), declined 	26% 	and
28% 	in the 	second 	quarter and first 	six 	months of 	2020, respectively, driven by ongoing biosimilar competition in the Company’s marketing territories in Europe.
The Company lost market exclusivity for 	Remicade 	in major European markets in 2015 and no longer has market exclusivity in any of its marketing territories. The
Company is experiencing pricing and volume declines in these markets as a result of biosimilar competition and expects the declines to continue.
Virology
Three Months Ended
June 30,
% Change
Excluding
Foreign
Exchange
Six Months Ended
June 30,
% Change
Excluding
Foreign
Exchange	($ in millions) 	2020 	2019 	% Change 	2020 	2019 	% Change
Isentress/Isentress HD 	$ 	196 	$ 	247 	(21)% 	(17)% 	$ 	441 	$ 	502 	(12)% 	(9)%
Zepatier 	39 	108 	(63)% 	(62)% 	94 	221 	(57)% 	(56)%
Global combined sales of 	Isentress/Isentress HD 	(raltegravir), an HIV integrase inhibitor for use in combination with other antiretroviral agents for the
treatment of HIV-1 infection, declined 	21% 	in the 	second 	quarter of 	2020 	primarily driven by competitive pressure in the United States and in the EU, as well as
the timing of shipments in Russia. Worldwide sales declined 	12% 	in the first 	six 	months of 	2020 	primarily due to lower sales in the United States and in the EU,
partially offset by higher volumes in Russia.
Global sales of 	Zepatier, a treatment for adult patients with chronic hepatitis C virus genotype (GT) 1 or GT4 infection, declined 	63% 	and 	57% 	in the
second 	quarter and first 	six 	months of 2020, respectively, primarily driven by lower demand in the EU, the United States, and the Asia Pacific region due to
competition and declining patient volumes, coupled with the impact of the COVID-19 pandemic.
Cardiovascular
Three Months Ended
June 30,
% Change
Excluding
Foreign
Exchange
Six Months Ended
June 30,
% Change
Excluding
Foreign
Exchange	($ in millions) 	2020 	2019 	% Change 	2020 	2019 	% Change
Zetia/Vytorin 	$ 	175 	$ 	232 	(24)% 	(23)% 	$ 	374 	$ 	470 	(20)% 	(19)%
Atozet 	115 	92 	25 	% 	28 	% 	238 	186 	28 	% 	31 	%
Rosuzet 	31 	52 	(41)% 	(40)% 	63 	66 	(5)% 	(2)%
Alliance Revenue - Adempas 	(1) 	79 	51 	54 	% 	54 	% 	133 	94 	41 	% 	41 	%
Adempas 	57 	53 	8 	% 	9 	% 	113 	100 	12 	% 	14 	%
(1) 	Alliance revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3 to the
condensed consolidated financial statements).
Combined global sales of 	Zetia 	(marketed in most countries outside the United States as 	Ezetrol) and 	Vytorin 	(marketed outside the United States as
Inegy), medicines for lowering LDL cholesterol, declined 	24% 	and 	20% 	in the 	second 	quarter and first 	six 	months of 	2020, respectively, primarily due to generic
competition for 	Ezetrol 	and 	Inegy 	in the EU. The EU patents for 	Ezetrol 	and 	Inegy 	expired in April 2018 and April 2019, respectively. The Company expects the
sales declines in these markets to continue. The sales decline was also attributable to loss of exclusivity in Australia. The patent that provided market exclusivity
for 	Ezetrol 	in Japan expired in September 2019 and generic competition began in the second quarter of 2020. These declines were partially offset by higher demand
for 	Ezetrol 	in China.
- 	36 	-

-- 37 of 54 --

Sales of 	Atozet 	(ezetimibe and atorvastatin) (marketed outside of the United States), a medicine for lowering LDL cholesterol, grew 	25% 	and 	28% 	in
the 	second 	quarter and first 	six 	months of 	2020, respectively, primarily due to higher demand in most markets, particularly in the EU and in Japan.
Sales of 	Rosuzet 	(ezetimibe and rosuvastatin) (marketed outside of the United States), a medicine for lowering LDL cholesterol, declined 	41% 	and 	5%
in the 	second 	quarter and first 	six 	months of 	2020, respectively, due to prior year launch buy-in in Japan. In the first six months of 	2020, the decline was partially
offset by higher demand in Korea.
Adempas (riociguat), a cardiovascular drug for the treatment of pulmonary arterial hypertension, is part of a worldwide clinical development
collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Adempas (see Note 3 to the condensed
consolidated financial statements). Revenue from Adempas includes Merck’s share of profits from the sale of Adempas in Bayer’s marketing territories, which
grew 	54% 	and 	41% 	in the 	second 	quarter and first 	six 	months of 	2020, respectively, as well as sales in Merck’s marketing territories, which grew 	8% 	and 	12% 	in
the 	second 	quarter and first 	six 	months of 	2020, respectively.
Diabetes
Three Months Ended
June 30,
% Change
Excluding
Foreign
Exchange
Six Months Ended
June 30,
% Change
Excluding
Foreign
Exchange	($ in millions) 	2020 	2019 	% Change 	2020 	2019 	% Change
Januvia/Janumet 	$ 	1,344 	$ 	1,441 	(7)% 	(5)% 	$ 	2,621 	$ 	2,795 	(6)% 	(5)%
Worldwide combined sales of 	Januvia 	and 	Janumet, medicines that help lower blood sugar levels in adults with type 2 diabetes, declined 	7% 	and 	6% 	in
the 	second 	quarter and first 	six 	months of 	2020, respectively. The declines were primarily due to continued pricing pressure in the United States and lower demand
in certain markets resulting from the COVID-19 pandemic, partially offset by higher demand in China. The Company expects U.S. pricing pressure to continue.
The patents that provide market exclusivity for 	Januvia 	and 	Janumet 	in the United States expire in July 2022 (although six-month pediatric exclusivity may extend
this date). The patent that provides market exclusivity for 	Januvia 	in the EU expires in July 2022 (although pediatric exclusivity has recently been granted which
may extend this date to September 2022 and the Company is applying in individual countries for the extensions). The supplementary patent certificate that provides
market exclusivity for 	Janumet 	in the EU expires in April 2023. The Company anticipates sales of 	Januvia 	and 	Janumet 	in these markets will decline substantially
after these patent expiries.
Women’s Health
Three Months Ended
June 30,
% Change
Excluding
Foreign
Exchange
Six Months Ended
June 30,
% Change
Excluding
Foreign
Exchange	($ in millions) 	2020 	2019 	% Change 	2020 	2019 	% Change
Implanon/Nexplanon 	$ 	132 	$ 	183 	(28)% 	(26)% 	$ 	326 	$ 	382 	(15)% 	(13)%
NuvaRing 	63 	240 	(74)% 	(73)% 	126 	459 	(73)% 	(72)%
Global sales of 	Implanon/Nexplanon, a single-rod subdermal contraceptive implant, declined 	28% 	and 	15% 	in the 	second 	quarter and first 	six 	months of
2020, respectively, primarily due to lower demand in the United States and in the EU resulting from the COVID-19 pandemic, partially offset by higher demand in
Latin America.
Worldwide sales of 	NuvaRing, a vaginal contraceptive product, declined 	74% 	and 	73% 	in the 	second 	quarter and first 	six 	months of 	2020, respectively,
due to generic competition in the United States. The patent that provided U.S. market exclusivity for 	NuvaRing 	expired in April 2018 and generic competition
began in December 2019. Accordingly, the Company is experiencing a rapid and substantial decline in U.S. 	NuvaRing 	sales and expects the decline to continue.
Biosimilars
Three Months Ended
June 30,
% Change
Excluding
Foreign
Exchange
Six Months Ended
June 30,
% Change
Excluding
Foreign
Exchange	($ in millions) 	2020 	2019 	% Change 	2020 	2019 	% Change
Biosimilars 	$ 	60 	$ 	78 	(23)% 	(21)% 	$ 	128 	$ 	121 	6% 	7%
Biosimilar products are marketed by the Company pursuant to an agreement with Samsung Bioepis Co., Ltd. (Samsung) to develop and commercialize
multiple pre-specified biosimilar candidates. Currently, the Company markets Renflexis (infliximab-abda), a biosimilar to Remicade (infliximab) for the treatment
of certain inflammatory diseases; Ontruzant (trastuzumab-dttb), a biosimilar to Herceptin (trastuzumab) for the treatment of human epidermal growth factor
receptor 2 (HER2)-positive breast cancer and HER2 overexpressing gastric cancer; and Brenzys (etanercept biosimilar), a biosimilar to Enbrel for the treatment of
certain
- 	37 	-

-- 38 of 54 --

inflammatory diseases. Merck’s commercialization territories under the agreement vary by product. Sales of biosimilars declined 	23% 	in the 	second 	quarter of
2020 	primarily due to lower volumes for Brenzys in Brazil due in part to the timing of shipments. Sales of biosimilars grew 	6% 	in the first 	six 	months of 	2020
driven by continued post-launch uptake of Renflexis in United States and Canada and Ontruzant in the EU, partially offset by lower sales of Brenzys in Brazil.
In April 2020, Merck announced the U.S. launch of Ontruzant, which was approved by the FDA in January 2019.
Animal Health Segment
Three Months Ended
June 30,
% Change
Excluding
Foreign
Exchange
Six Months Ended
June 30,
% Change
Excluding
Foreign
Exchange	($ in millions) 	2020 	2019 	% Change 	2020 	2019 	% Change
Livestock 	$ 	648 	$ 	671 	(3)% 	3% 	$ 	1,386 	$ 	1,282 	8% 	13%
Companion Animal 	453 	453 	— 	% 	3% 	928 	867 	7% 	9%
Sales of livestock products declined 	3% 	in the 	second 	quarter of 	2020 	primarily driven by lower demand attributable to the COVID-19 pandemic and
the unfavorable effect of foreign exchange, partially offset by an additional month of sales in 2020 related to the April 2019 acquisition of Antelliq Corporation
(Antelliq) (see Note 2 to the condensed consolidated financial statements). Sales of livestock products grew 	8% 	in the first 	six 	months of 	2020 	largely driven by the
Antelliq acquisition. Sales of companion animal products were flat in the 	second 	quarter of 	2020 	as higher demand for the 	Bravecto 	(fluralaner) line of products for
parasitic control was offset by lower demand for companion animal vaccines due to reduced veterinary access resulting from the COVID-19 pandemic. Companion
animal sales grew 	7% 	in the first 	six 	months of 	2020 	primarily driven by higher sales of the 	Bravecto 	line of products, partially offset by lower demand for other
companion animal products attributable to the COVID-19 pandemic.
Costs, Expenses and Other
Three Months Ended
June 30,
Six Months Ended
June 30,
($ in millions) 	2020 	2019 	% Change 	2020 	2019 	% Change
Cost of sales 	$ 	3,159 	$ 	3,401 	(7)% 	$ 	6,471 	$ 	6,453 	— 	%
Selling, general and administrative 	2,378 	2,712 	(12)% 	4,933 	5,138 	(4)%
Research and development 	2,123 	2,189 	(3)% 	4,331 	4,119 	5 	%
Restructuring costs 	83 	59 	41 	% 	155 	212 	(27)%
Other (income) expense, net 	(390) 	140 	* 	(318) 	327 	*
$ 	7,353 	$ 	8,501 	(14)% 	15,572 	16,249 	(4)%
* Greater than 100%.
Cost of Sales
Cost of sales declined 	7% 	in the 	second 	quarter of 	2020 	and were essentially flat in the first 	six 	months of 	2020. Cost of sales includes the amortization
of intangible assets recorded in connection with business acquisitions, which totaled $281 million and $371 million in the 	second 	quarter of 	2020 	and 	2019,
respectively, and $573 million and $768 million in the first 	six 	months of 2020 and 2019, respectively. Cost of sales also includes the amortization of amounts
capitalized in connection with collaborations of $298 million and $124 million in the 	second 	quarter of 	2020 	and 	2019, respectively, and $388 million and $222
million in the first 	six 	months of 2020 and 2019, respectively. Additionally, costs include intangible asset impairment charges of 	$69 million 	and 	$81 million 	in the
second 	quarter and first 	six 	months of 2019 related to marketed products recorded in connection with business acquisitions. The Company may recognize
additional impairment charges in the future related to intangible assets that were measured at fair value and capitalized in connection with business acquisitions and
such charges could be material. Also included in cost of sales are expenses associated with restructuring activities which amounted to 	$25 million 	and 	$65 million
in the 	second 	quarter of 	2020 	and 	2019, respectively, and 	$93 million 	and 	$99 million 	in the first 	six 	months of 2020 and 2019, respectively, including accelerated
depreciation and asset write-offs related to the planned sale or closure of manufacturing facilities. Separation costs associated with manufacturing-related
headcount reductions have been incurred and are reflected in 	Restructuring costs 	as discussed below.
Gross margin was 70.9% in the 	second 	quarter of 	2020 	compared with 71.1% in the 	second 	quarter of 	2019. The gross margin decline reflects higher
amortization of unfavorable manufacturing variances and intangible assets (noted above), largely offset by the favorable effects of foreign exchange, product mix
and lower restructuring costs. Gross margin was 71.8% in the first 	six 	months of 2020 compared with 71.4% in the first 	six 	months of 2019. The gross margin
improvement was primarily driven by favorable product mix, partially offset by the unfavorable effects of pricing pressure, manufacturing variances, royalties, and
inventory write-offs.
- 	38 	-

-- 39 of 54 --

Selling, General and Administrative
Selling, general and administrative (SG&A) expenses declined 	12% 	and 	4% 	in the 	second 	quarter and first 	six 	months of 	2020, respectively, primarily
due to lower promotional, selling, and administrative costs, including reduced travel and fewer meetings, due in part to the COVID-19 pandemic, and the favorable
effect of foreign exchange, partially offset by costs related to the planned spin-off of Organon. Transaction costs related to the acquisition of ArQule also
contributed to the increase in SG&A expenses in the first 	six 	months of 2020 (see Note 2 to the condensed consolidated financial statements).
Research and Development
Research and development (R&D) expenses declined 	3% 	in the 	second 	quarter of 	2020 	reflecting a decrease in the estimated fair value measurement of
liabilities for contingent consideration, as well as lower laboratory supply costs, reduced travel and fewer meetings due to the COVID-19 pandemic, partially offset
by higher expenses related to clinical development and increased investment in discovery research and early drug development. R&D expenses increased 	5% 	in the
first 	six 	months of 2020 primarily driven by higher clinical development and discovery research spending, as well as higher licensing and restructuring costs,
partially offset by lower costs associated with the COVID-19 pandemic and the favorable effect of foreign exchange.
R&D expenses are comprised of the costs directly incurred by Merck Research Laboratories (MRL), the Company’s research and development division
that focuses on human health-related activities, which were $1.5 billion in both the 	second 	quarter of 	2020 	and 	2019, and $3.0 billion and $2.9 billion in the first 	six
months of 2020 and 2019, respectively. Also included in R&D expenses are Animal Health research costs, licensing costs and costs incurred by other divisions in
support of R&D activities, including depreciation, production and general and administrative, which in the aggregate were approximately $645 million and $715
million for the 	second 	quarter of 	2020 	and 	2019, respectively, and $1.3 billion in both the first 	six 	months of 2020 and 2019. In addition, R&D expenses include
expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration recorded in connection with business
acquisitions. The Company recorded a net reduction in expenses of $82 million in the second quarter of 2020 and $49 million and $38 million in the first 	six
months of 2020 and 2019, respectively, related to the changes in these estimates. R&D expenses also reflect 	$31 million 	and 	$48 million 	of accelerated
depreciation costs in connection with restructuring activities in the 	second 	quarter and first 	six 	months of 	2020, respectively.
Restructuring Costs
In early 2019, Merck approved a new global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further
optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. This program is a continuation of the Company’s
plant rationalization, builds on prior restructuring programs and does not include any actions associated with the planned spin-off of Organon. As the Company
continues to evaluate its global footprint and overall operating model, it subsequently identified additional actions under the Restructuring Program, and could
identify further actions over time. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of
2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately 	$2.5 billion. The Company expects
to record charges of approximately 	$800 million 	in 	2020 	related to the Restructuring Program. The Company anticipates the actions under the Restructuring
Program to result in annual net cost savings of approximately 	$900 million 	by the end of 2023. Actions under previous global restructuring programs have been
substantially completed.
Restructuring costs, primarily representing separation and other related costs associated with these restructuring activities, were 	$83 million 	and 	$59
million 	for the 	second 	quarter of 	2020 	and 	2019, respectively, and 	$155 million 	and 	$212 million 	in the first 	six 	months of 2020 and 2019, respectively. Separation
costs incurred were associated with actual headcount reductions, as well as estimated expenses under existing severance programs for headcount reductions that
were probable and could be reasonably estimated. Also included in restructuring costs are asset abandonment, facility shut-down and other related costs, as well as
employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based
compensation plan costs. For segment reporting, restructuring costs are unallocated expenses.
Additional costs associated with the Company’s restructuring activities are included in 	Cost of sales, 	Selling, general and administrative 	expenses and
Research and development 	costs. The Company recorded aggregate pretax costs of 	$150 million 	and 	$159 million 	in the 	second 	quarter of 	2020 	and 	2019,
respectively, and 	$318 million 	and 	$346 million 	in the first 	six 	months of 2020 and 2019, respectively, related to restructuring program activities (see Note 4 to the
condensed consolidated financial statements).
Other (Income) Expense, Net
For details on the components of 	Other (income) expense, net 	see Note 12 to the condensed consolidated financial statements.
- 	39 	-

-- 40 of 54 --

Segment Profits
Three Months Ended
June 30,
Six Months Ended
June 30,
($ in millions) 	2020 	2019 	2020 	2019
Pharmaceutical segment profits 	$ 	6,560 	$ 	7,115 	$ 	14,036 	$ 	13,690
Animal Health segment profits 	407 	405 	885 	820
Other non-reportable segment profits 	— 	(2) 	2 	—
Other 	(3,448) 	(4,259) 	(7,566) 	(8,184)
Income before taxes 	$ 	3,519 	$ 	3,259 	$ 	7,357 	$ 	6,326
Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as SG&A expenses directly incurred by the segment. Animal
Health segment profits are comprised of segment sales, less all cost of sales, as well as SG&A expenses and research and development costs directly incurred by
the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included
in segment profits as described above, research and development expenses incurred by MRL, or general and administrative expenses, nor the cost of financing
these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these
divisions and, therefore, they are not included in segment profits. Also excluded from the determination of segment profits are costs related to restructuring
activities and acquisition and divestiture-related costs, including the amortization of purchase accounting adjustments, intangible asset impairment charges, and
changes in the estimated fair value measurement of liabilities for contingent consideration. Additionally, segment profits do not reflect other expenses from
corporate and manufacturing cost centers and other miscellaneous income or expense. These unallocated items are reflected in “Other” in the above table. Also
included in “Other” are miscellaneous corporate profits (losses), as well as operating profits (losses) related to third-party manufacturing sales.
Pharmaceutical segment profits declined 8% in the 	second 	quarter of 	2020 	largely due to lower sales and the unfavorable effect of foreign exchange,
partially offset by lower selling and promotional costs. Pharmaceutical segment profits grew 3% in the first 	six 	months of 	2020 	driven primarily by higher sales, as
well as lower selling and promotional costs, partially offset by the unfavorable effect of foreign exchange. Animal Health segment profits grew 1% in the 	second
quarter of 2020 reflecting lower selling and promotional costs, largely offset by lower sales and the unfavorable effect of foreign exchange. Animal Health segment
profits grew 8% in the first 	six 	months of 	2020 	reflecting higher sales driven by the Antelliq acquisition, partially offset by higher research costs and the
unfavorable effect of foreign exchange.
Taxes on Income
The effective income tax rates of 	14.5% 	and 	18.9% 	for the 	second 	quarter of 	2020 	and 	2019, respectively, and 	15.3% 	and 	13.0% 	for the first 	six 	months
of 2020 and 2019, respectively, reflect the impacts of acquisition and divestiture-related costs and restructuring costs, partially offset by the beneficial impact of
foreign earnings. In addition, the effective income tax rate for the first 	six 	months of 2019 reflects the favorable impact of a 	$360 million 	net tax benefit related to
the settlement of certain federal income tax matters.
In the first quarter of 2019, the Internal Revenue Service (IRS) concluded its examinations of Merck’s 2012-2014 U.S. federal income tax returns. As a
result, the Company was required to make a payment of 	$107 million. The Company’s reserves for unrecognized tax benefits for the years under examination
exceeded the adjustments relating to this examination period and therefore the Company recorded a 	$360 million 	net tax benefit in the first 	six 	months of 2019.
This net benefit reflects reductions in reserves for unrecognized tax benefits for tax positions relating to the years that were under examination, partially offset by
additional reserves for tax positions not previously reserved for.
Net Loss Attributable to Noncontrolling Interests
Net loss attributable to noncontrolling interests of 	$26 million 	for the 	second 	quarter of 	2019 	and 	$79 million 	for the first 	six 	months of 2019 includes
the portion of goodwill impairment charges related to certain businesses in the Healthcare Services segment that are attributable to noncontrolling interests.
Net Income and Earnings per Common Share
Net income attributable to Merck & Co., Inc. was 	$3.0 billion 	for the 	second 	quarter of 	2020 	compared with 	$2.7 billion 	for the 	second 	quarter of 	2019
and was 	$6.2 billion 	for the first 	six 	months of 	2020 	compared with 	$5.6 billion 	for the first 	six 	months of 	2019. Earnings per common share assuming dilution
attributable to Merck & Co., Inc. common shareholders (EPS) for the 	second 	quarter of 	2020 	were 	$1.18 	compared with 	$1.03 	in the 	second 	quarter of 	2019 	and
were 	$2.45 	for the first 	six 	months of 	2020 	compared with 	$2.15 	for the first 	six 	months of 	2019.
- 	40 	-

-- 41 of 54 --

Non-GAAP Income and Non-GAAP EPS
Non-GAAP income and non-GAAP EPS are alternative views of the Company’s performance that Merck is providing because management believes
this information enhances investors’ understanding of the Company’s results as it permits investors to understand how management assesses performance. Non-
GAAP income and non-GAAP EPS exclude certain items because of the nature of these items and the impact that they have on the analysis of underlying business
performance and trends. The excluded items (which should not be considered non-recurring) consist of acquisition and divestiture-related costs, restructuring costs
and certain other items. These excluded items are significant components in understanding and assessing financial performance. Non-GAAP income and non-
GAAP EPS are important internal measures for the Company. Senior management receives a monthly analysis of operating results that includes non-GAAP EPS.
Management uses these measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In
addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. Since non-GAAP income and non-GAAP EPS are not
measures determined in accordance with GAAP, they have no standardized meaning prescribed by GAAP and, therefore, may not be comparable to the calculation
of similar measures of other companies. The information on non-GAAP income and non-GAAP EPS should be considered in addition to, but not as a substitute for
or superior to, net income and EPS prepared in accordance with generally accepted accounting principles in the United States (GAAP).
A reconciliation between GAAP financial measures and non-GAAP financial measures is as follows:
Three Months Ended
June 30,
Six Months Ended
June 30,
($ in millions except per share amounts) 	2020 	2019 	2020 	2019
Income before taxes as reported under GAAP 	$ 	3,519 	$ 	3,259 	$ 	7,357 	$ 	6,326
Increase (decrease) for excluded items:
Acquisition and divestiture-related costs 	443 	660 	1,043 	1,208
Restructuring costs 	150 	159 	318 	346
Other 	(16) 	48 	(16) 	48
Non-GAAP income before taxes 	4,096 	4,126 	8,702 	7,928
Taxes on income as reported under GAAP 	509 	615 	1,128 	820
Estimated tax benefit on excluded items 	(1) 	95 	145 	260 	274
Net tax benefit from the settlement of certain federal income tax matters 	— 	— 	— 	360
Tax charge related to finalization of treasury regulations for the Tax Cuts and Job Act of 2017 	— 	— 	— 	(67)
Non-GAAP taxes on income 	604 	760 	1,388 	1,387
Non-GAAP net income 	3,492 	3,366 	7,314 	6,541
Less: Net income (loss) attributable to noncontrolling interests as reported under GAAP 	8 	(26) 	8 	(79)
Acquisition and divestiture-related costs attributable to noncontrolling interests 	— 	36 	— 	89
Non-GAAP net income attributable to noncontrolling interests 	8 	10 	8 	10
Non-GAAP net income attributable to Merck & Co., Inc. 	$ 	3,484 	$ 	3,356 	$ 	7,306 	$ 	6,531
EPS assuming dilution as reported under GAAP 	$ 	1.18 	$ 	1.03 	$ 	2.45 	$ 	2.15
EPS difference 	0.19 	0.27 	0.42 	0.37
Non-GAAP EPS assuming dilution 	$ 	1.37 	$ 	1.30 	$ 	2.87 	$ 	2.52
(1) 	The estimated tax impact on the excluded items is determined by applying the statutory rate of the originating territory of the non-GAAP adjustments.
Acquisition and Divestiture-Related Costs
Non-GAAP income and non-GAAP EPS exclude the impact of certain amounts recorded in connection with business acquisitions and divestitures.
These amounts include the amortization of intangible assets and amortization of purchase accounting adjustments to inventories, as well as intangible asset
impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Also excluded are
integration, transaction, and certain other costs associated with business acquisitions and divestitures.
Restructuring Costs
Non-GAAP income and non-GAAP EPS exclude costs related to restructuring actions (see Note 4 to the condensed consolidated financial statements).
These amounts include employee separation costs and accelerated depreciation associated with facilities to be closed or divested. Accelerated depreciation costs
represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be
closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions.
- 	41 	-

-- 42 of 54 --

Restructuring costs also include asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement
and termination charges associated with pension and other postretirement benefit plans and share-based compensation costs.
Certain Other Items
Non-GAAP income and non-GAAP EPS exclude certain other items. These items are adjusted for after evaluating them on an individual basis,
considering their quantitative and qualitative aspects. Typically, these consist of items that are unusual in nature, significant to the results of a particular period or
not indicative of future operating results. Excluded from non-GAAP income and non-GAAP EPS in 2019 is a net tax benefit related to the settlement of certain
federal income tax matters (see Note 13 to the condensed consolidated financial statements) and a tax charge related to the finalization of U.S. treasury regulations
related to the Tax Cuts and Jobs Act of 2017.
Research and Development Update
In July 2020, the FDA accepted for priority review the New Drug Application (NDA) for vericiguat, an orally administered sGC stimulator, to reduce
the risk of cardiovascular death and heart failure hospitalization following a worsening heart failure event in patients with symptomatic chronic heart failure with
reduced ejection fraction, in combination with other heart failure therapies. The FDA set a Prescription Drug User Fee Act (PDUFA), or target action, date of
January 20, 2021. Vericiguat is being jointly developed with Bayer (see Note 3 to the condensed consolidated financial statements). The application is based on
results from the Phase 3 VICTORIA trial, which is the first contemporary outcomes study focused exclusively on a population with worsening chronic heart failure
who are at high risk for cardiovascular mortality and repeated heart failure hospitalizations. Data from VICTORIA were presented at the virtual American College
of Cardiology’s 69th Annual Scientific Session together with World Congress of Cardiology and published in 	The New England Journal of Medicine. Vericiguat is
also under review in the EU and in Japan. Merck and Bayer plan to share VICTORIA data with regulatory authorities worldwide.
Koselugo (selumetinib) is under review in the EU for the treatment of pediatric patients two years of age and older with NF1 who have symptomatic,
inoperable PN based on positive results from the NCI CTEP-sponsored Phase 2 SPRINT Stratum 1 trial. Koselugo was approved by the FDA in April 2020.
Koselugo is being jointly developed and commercialized with AstraZeneca globally (see Note 3 to the condensed consolidated financial statements).
Keytruda 	is an anti-PD-1 therapy approved for the treatment of many cancers that is in clinical development for expanded indications. These approvals
were the result of a broad clinical development program that currently consists of more than 1,200 clinical trials, including more than 850 trials that combine
Keytruda 	with other cancer treatments. These studies encompass more than 30 cancer types including: biliary tract, cervical, colorectal, cutaneous squamous cell,
endometrial, gastric, glioblastoma, head and neck, hepatocellular, Hodgkin lymphoma, non-Hodgkin lymphoma, melanoma, mesothelioma, nasopharyngeal, non-
small-cell lung, ovarian, PMBCL, prostate, renal, small-cell lung, triple-negative breast and urothelial, many of which are currently in Phase 3 clinical
development. Further trials are being planned for other cancers.
In July 2020, the FDA accepted and granted Priority Review for a supplemental Biologics License Application (BLA) seeking accelerated approval for
Keytruda 	in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic 	triple-negative breast cancer (TNBC)
whose tumors express PD-L1 (CPS ≥10). The application was based on data from the KEYNOTE-355 trial in which 	Keytruda 	plus chemotherapy demonstrated a
statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with chemotherapy alone in patients whose tumors
expressed PD-L1 at CPS ≥10. 	In patients whose tumors expressed PD-L1 with CPS ≥1, 	Keytruda 	plus chemotherapy improved PFS versus chemotherapy alone,
however these results did not meet statistical significance. 	These data were presented at the virtual scientific program of the 2020 American Society of Clinical
Oncology (ASCO) Annual Meeting. As previously announced, the trial will continue without changes to evaluate the other dual primary endpoint of overall
survival (OS). The FDA set a PDUFA date of November 28, 2020.
Also in July 2020, the FDA accepted for standard review a supplemental BLA for 	Keytruda 	for the treatment of patients with high-risk, early-stage
TNBC, in combination with chemotherapy as neoadjuvant treatment, and then as a single agent as adjuvant treatment after surgery. The application was based on
data from the KEYNOTE-522 trial in which neoadjuvant 	Keytruda 	plus chemotherapy resulted in a statistically significant increase in pathologic complete
response in patients with early-stage TNBC, regardless of PD-L1 expression. The 	Keytruda 	regimen also demonstrated a favorable trend for the other dual primary
endpoint of event-free survival. 	An interim analysis for this study was conducted by the Independent Data Monitoring Committee (DMC). Based on the
recommendation of the DMC, the study continues to evaluate event-free survival. 	Data from the KEYNOTE-522 trial were presented at the European Society for
Medical Oncology 2019 Congress. As previously announced, 	Keytruda 	plus chemotherapy was granted Breakthrough Therapy designation by the FDA in
September 2019 for the neoadjuvant treatment of patients with high-risk, early-stage TNBC. The PDUFA date for this application is March 29, 2021.
Additionally in July 2020, the FDA accepted and granted Priority Review for a new supplemental BLA for 	Keytruda 	as monotherapy for the second-
line treatment of adult patients with relapsed or refractory cHL based on data from the pivotal
- 	42 	-

-- 43 of 54 --

Phase 3 KEYNOTE-204 trial, in which 	Keytruda 	demonstrated a significant improvement in PFS compared to brentuximab vedotin (BV), a current standard of
care in this patient population. The FDA set a PDUFA date of October 30, 2020. KEYNOTE-204 also serves as the confirmatory trial for the 	Keytruda 	accelerated
approval hematology indications and as previously announced the Company plans to submit these data to global regulatory authorities this year. The Committee for
Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) announced the start of a procedure to extend the currently approved
therapeutic indication for the treatment of relapsed or refractory cHL in adults to an earlier line of therapy and to include pediatric patients based on KEYNOTE-
204. Data from KEYNOTE-204 were presented during the virtual scientific program of the 2020 ASCO Annual Meeting.
Keytruda 	is under review in Japan as monotherapy for the second-line treatment of advanced or metastatic esophageal or esophagogastric junction
carcinoma based on the results of the Phase 3 KEYNOTE-181 trial. The 	Keytruda 	review in Japan for both monotherapy and in combination with chemotherapy
for the first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma based on results from the pivotal Phase 3 KEYNOTE-062 trial was
withdrawn in June 2020.
Keytruda 	is also under review in the EU for the first-line treatment of patients with MSI-H or mismatch repair deficient unresectable or metastatic
colorectal cancer based on the results from the Phase 3 KEYNOTE-177 trial. 	Keytruda 	was approved for this indication by the FDA in June 2020.
In addition to the Breakthrough Therapy designation from the FDA for the combination of 	Keytruda 	with neoadjuvant chemotherapy for the treatment
of high-risk, early-stage TNBC noted above, 	Keytruda 	also received Breakthrough Therapy designation from the FDA in February 2020 for the combination of
Keytruda 	with PADCEV (enfortumab vedotin-ejfv), in the first-line setting for the treatment of patients with unresectable locally advanced or metastatic urothelial
cancer who are not eligible for cisplatin-containing chemotherapy. The FDA’s Breakthrough Therapy designation is intended to expedite the development and
review of a candidate that is planned for use, alone or in combination, to treat a serious or life-threatening disease or condition when preliminary clinical evidence
indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.
In June 2020, Merck announced that the Phase 3 KEYNOTE-361 trial evaluating 	Keytruda 	in combination with chemotherapy for the first-line
treatment of patients with advanced or metastatic urothelial carcinoma (bladder cancer) did not meet its pre-specified dual primary endpoints of OS or PFS,
compared with standard of care chemotherapy. In the final analysis of the study, there was an improvement in OS and PFS for patients treated with 	Keytruda 	in
combination with chemotherapy compared to chemotherapy alone; however, these results did not meet statistical significance per the pre-specified statistical plan.
The monotherapy arm of the study was not formally tested, since superiority was not reached for OS or PFS in the 	Keytruda 	combination arm. 	Keytruda 	has three
FDA-approved bladder cancer indications across multiple stages of bladder cancer. Additionally, Merck has an extensive clinical development program in bladder
cancer and is continuing to evaluate 	Keytruda 	as monotherapy and in combination with other anti-cancer therapies across several disease settings (i.e., metastatic,
muscle invasive bladder cancer, and non-muscle invasive bladder cancer).
Additionally in May 2020, Merck announced positive results from two studies from the Company’s lung cancer research program. Initial results from
the Phase 2 KEYNOTE-799 trial evaluating 	Keytruda 	plus concurrent chemoradiation therapy demonstrated an objective response rate (ORR) of 67.0% in Cohort
A (squamous and nonsquamous NSCLC patients who received paclitaxel plus carboplatin) and 56.6% in Cohort B (nonsquamous NSCLC patients who received
cisplatin plus pemetrexed) in untreated patients with unresectable, locally advanced stage III NSCLC.
In May 2020, Merck and Eisai presented data from analyses of two trials evaluating 	Keytruda 	plus Lenvima at the 2020 ASCO Annual Meeting, in
which the 	Keytruda 	plus Lenvima combination demonstrated clinically meaningful ORR: the KEYNOTE-524/Study 116 trial in patients with unresectable HCC
with no prior systemic therapy and the KEYNOTE-146/Study 111 trial in patients with metastatic clear cell renal cell carcinoma (ccRCC) who progressed
following immune checkpoint inhibitor therapy.
In July 2020, Merck and Eisai announced that the FDA issued a Complete Response Letter (CRL) regarding Merck’s and Eisai’s applications seeking
accelerated approval of 	Keytruda 	plus Lenvima for the first-line treatment of patients with unresectable HCC based on data from the Phase 1b KEYNOTE-
524/Study 116 trial, which showed clinically meaningful efficacy in the single-arm setting. These data supported a Breakthrough Therapy designation granted by
the FDA in July 2019. Ahead of the PDUFA action dates of Merck’s and Eisai’s applications, another combination therapy was approved based on a randomized,
controlled trial that demonstrated OS. Consequently, the CRL stated that Merck’s and Eisai’s applications do not provide evidence that 	Keytruda 	in combination
with Lenvima represents a meaningful advantage over available therapies for the treatment of unresectable or metastatic HCC with no prior systemic therapy for
advanced disease. Since the applications for KEYNOTE-524/Study 116 no longer meet the criteria for accelerated approval, both companies plan to work with the
FDA to take appropriate next steps, which include conducting a well-controlled clinical trial that demonstrates substantial evidence of effectiveness and the clinical
benefit of the combination. As such, LEAP-002, the Phase 3 trial evaluating the 	Keytruda 	plus Lenvima combination
- 	43 	-

-- 44 of 54 --

as a first-line treatment for advanced HCC, is currently underway and fully enrolled. The CRL does not impact the current approved indications for 	Keytruda 	or for
Lenvima.
Lynparza is an oral PARP inhibitor currently approved for certain types of advanced ovarian, breast, pancreatic and prostate cancers being co-
developed for multiple cancer types as part of a collaboration with AstraZeneca (see Note 3 to the condensed consolidated financial statements).
Lynparza is under review in the EU in combination with bevacizumab for the maintenance treatment of women with advanced ovarian cancer whose
disease showed a complete or partial response to first-line treatment with platinum-based chemotherapy and bevacizumab based on the results from the pivotal
Phase 3 PAOLA-1 trial. The FDA approved Lynparza for this indication in May 2020.
Lynparza is also under review in the EU for the treatment of patients with mCRPC and deleterious or suspected deleterious germline or somatic HRR
gene mutations, who have progressed following prior treatment with a new hormonal agent based on positive results from the Phase 3 PROfound trial. This
indication was approved by the FDA in May 2020 and is under review in other jurisdictions. In April 2020, Merck and AstraZeneca announced further positive
results from the Phase 3 PROfound trial which showed a statistically significant and clinically meaningful improvement in the key secondary endpoint of OS with
Lynparza vs. enzalutamide or abiraterone in men with mCRPC selected for 	BRCA1/2 or 	ATM 	gene mutations, a subpopulation of HRR gene mutations.
In May 2020, the results from the Phase 3 GY004 trial, led by NRG Oncology and sponsored by the U.S. NCI, were presented at the 2020 ASCO
Annual Meeting. This follows the March 2020, Merck and AstraZeneca announcement of the high-level results from the Phase 3 GY004 trial that examined
primarily the efficacy and safety of investigational medicine cediranib in combination with Lynparza versus platinum-based chemotherapy in patients with
platinum-sensitive relapsed ovarian cancer. The trial did not meet the primary endpoint in the intent-to-treat population of a statistically significant improvement in
PFS with cediranib in combination with Lynparza vs. platinum-based chemotherapy.
In July 2020, the FDA granted Breakthrough Therapy designation to the hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor MK-6482, a novel
investigational candidate for the treatment of patients with von Hippel-Lindau (VHL) disease-associated RCC with nonmetastatic RCC tumors less than three
centimeters in size, unless immediate surgery is required. The FDA also granted orphan drug designation to MK-6482 for VHL disease. These designations are
based on data from a Phase 2 trial evaluating MK-6482 in patients with VHL-associated ccRCC, which were presented at the 2020 ASCO Annual Meeting.
In March 2020, Merck announced top-line efficacy results from two ongoing pivotal Phase 3 trials (COUGH-1 and COUGH-2) evaluating the efficacy
and safety of gefapixant (MK-7264), an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory or unexplained
chronic cough. In these studies, the primary efficacy endpoints were met for the gefapixant 45 mg twice daily treatment arms - demonstrating a statistically
significant decrease in 24-hour coughs per hour versus placebo. The gefapixant 15 mg twice daily treatment arms did not meet the primary efficacy endpoint in
either Phase 3 study. The detailed findings will be shared at an upcoming medical meeting.
In July 2020, Merck announced new analyses from the Phase 2b trial (NCT03272347) evaluating the safety and efficacy of islatravir, the company’s
investigational oral nucleoside reverse transcriptase translocation inhibitor (NRTTI), in combination with 	Pifeltro 	(doravirine), in adults with HIV-1 infection who
had not previously received antiretroviral treatment. The first sub-analysis further characterized the tolerability and safety profile of islatravir in combination with
doravirine (100 mg) through Week 48 across the three dose levels studied (0.25, 0.75, 2.25 mg). The second sub-analysis demonstrated that participants who
initiated treatment with islatravir and doravirine in combination with 3TC and switched to islatravir and doravirine maintained antiviral activity at Week 48 as
measured by HIV-1 RNA <50 copies/mL similar to 	Delstrigo 	(doravirine/lamivudine/tenofovir disoproxil fumarate), with low rates of protocol defined virologic
failure. These latest findings were made available during the 2020 International AIDS Conference. The primary endpoints and full study design of the Phase 2b
Week 48 trial results were originally presented at the 2019 International AIDS Society Conference on HIV Science.
In June 2020, Merck announced results from two initial Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, the Company’s
investigational 15-valent pneumococcal conjugate vaccine. Results from the PNEU-WAY (V114-018) study in adults 18 years of age or older living with HIV
showed that V114 elicited an immune response to all 15 serotypes included in the vaccine, including serotypes 22F and 33F. Results from the PNEU-FLU (V114-
021) study in healthy adults 50 years of age or older showed that V114 can be given concomitantly with the quadrivalent influenza vaccine. The V114 Phase 3
clinical development program is comprised of 16 trials investigating the safety, tolerability and immunogenicity of V114 in a variety of populations who are at
increased risk for pneumococcal disease including both healthy older adult and healthy pediatric populations, as well as people who are immunocompromised or
have certain chronic conditions. The Company plans to continue to work with the FDA and other regulatory authorities around the world on filing plans for
licensure of this vaccine as additional data from the Phase 3 program become available. These data were announced and published in the International Symposium
on Pneumococci and Pneumococcal Diseases (ISPPD) digital library in lieu of an in-person meeting.
- 	44 	-

-- 45 of 54 --

In May 2020, Merck and Pfizer Inc. announced the presentation of results from the Phase 3 VERTIS CV cardiovascular (CV) outcomes trial that
evaluated Steglatro (ertugliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, versus placebo, added to background standard of care treatment, in
patients with type 2 diabetes and atherosclerotic CV disease. The study met the primary endpoint of non-inferiority on major adverse CV events (MACE), which is
composed of a composite of CV death, nonfatal myocardial infarction or nonfatal stroke, compared to placebo. The key secondary endpoints of superiority for
Steglatro versus placebo for time to the first occurrence of the composite of CV death or hospitalization for heart failure, time to CV death alone and time to the
first occurrence of the composite of renal death, dialysis/transplant or doubling of serum creatinine from baseline were not met. While not a pre-specified
hypothesis for statistical testing, a reduction in hospitalization for heart failure was observed with Steglatro.
The chart below reflects the Company’s research pipeline as of July 31, 2020. Candidates shown in Phase 3 include specific products and the date such
candidate entered into Phase 3 development. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism or, if listed compounds
have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics are given MK-
number designations and vaccine candidates are given V-number designations. Except as otherwise noted, candidates in Phase 1, additional indications in the same
therapeutic area (other than with respect to cancer) and additional claims, line extensions or formulations for in-line products are not shown.
Phase 2 	Phase 3 (Phase 3 entry date) 	Under Review
Cancer
MK-1026
Hematological Malignancies
MK-1308(1)
Melanoma
Non-Small-Cell Lung
MK-1454(1)
Head and Neck
MK-3475 	Keytruda
Advanced Solid Tumors
MK-4280(1)
Hematological Malignancies
Non-Small-Cell Lung
MK-5890(1)
Non-Small-Cell Lung
MK-7339 Lynparza(2)(3)
Advanced Solid Tumors
MK-7684(1)
Melanoma
Non-Small-Cell Lung
MK-7902 Lenvima(1)(2)
Advanced Solid Tumors
V937
Melanoma
Chikungunya virus
V184
Cytomegalovirus
V160
HIV-1 Prevention
MK-8591 (islatravir)
Overgrowth Syndrome
MK-7075
Respiratory Syncytial Virus
MK-1654
SARS-CoV-2 Infection
MK-4482(2)
Schizophrenia
MK-8189
Cancer
MK-3475 	Keytruda
Biliary Tract (September 2019)
Breast (October 2015) (EU)
Cervical (October 2018) (EU)
Cutaneous Squamous Cell (August 2019) (EU)
Endometrial (August 2019) (EU)
Esophageal (December 2015) (EU)
Gastric (May 2015) (EU)
Hepatocellular (May 2016) (EU)
Mesothelioma (May 2018)
Nasopharyngeal (April 2016)
Ovarian (December 2018)
Prostate (May 2019)
Small-Cell Lung (May 2017) (EU)
MK-6482
Renal Cell (February 2020)
MK-7339 Lynparza(1)(2)
Non-Small-Cell Lung (June 2019)
MK-7902 Lenvima(1)(2)
Bladder (May 2019)
Endometrial (June 2018) (EU)
Head and Neck (February 2020)
Hepatocellular (May 2020)
Melanoma (March 2019)
Non-Small-Cell Lung (March 2019)
Cough
MK-7264 (gefapixant) (March 2018)
HIV-1 Infection
MK-8591A (doravirine/islatravir) (February 2020)
Pneumoconjugate Vaccine
V114 (June 2018)
New Molecular Entities/Vaccines
Heart Failure
MK-1242 (vericiguat)(2) 	(U.S.) (EU) (JPN)
Pediatric Neurofibromatosis Type 1
MK-5618 (selumetinib)(2) 	(EU)
Certain Supplemental Filings
Cancer
MK-3475 	Keytruda
• Metastatic Triple-Negative Breast Cancer
(KEYNOTE-355) (U.S.)
• Early-Stage Triple-Negative Breast Cancer
(KEYNOTE-522) (U.S.)
• Refractory Classical Hodgkin Lymphoma
(KEYNOTE-204) (U.S.) (EU)
• Recurrent Locally Advanced or Metastatic Esophageal
Cancer (KEYNOTE-180/KEYNOTE-181) (JPN)
• Unresectable or Metastatic MSI-H or dMMR Colorectal
Cancer (KEYNOTE-177) (EU)
MK-7339 Lynparza(2)
• First-Line Maintenance Newly Diagnosed Advanced
Ovarian Cancer (PAOLA) (EU)
• Metastatic Prostate Cancer (PROfound) (EU)
MK-7902 Lenvima(1)(2)
• First-Line Metastatic Hepatocellular Carcinoma
(KEYNOTE-524) (U.S.)(4)
• Thymic Carcinoma (NCCH1508/REMORA) (JPN)
Footnotes:
(1) 	Being developed in combination with 	Keytruda.
(2) 	Being developed in a collaboration.
(3) 	Being developed as monotherapy and in combination with 	Keytruda.
(4) 	In July 2020, the FDA issued a CRL for Merck’s and Eisai’s applications.
Merck and Eisai are reviewing the letter and will submit data to the FDA.
Liquidity and Capital Resources
($ in millions) 	June 30, 2020 	December 31, 2019
Cash and investments 	$ 	12,354 	$ 	11,919
Working capital 	7,165 	5,263
Total debt to total liabilities and equity 	34.1% 	31.2%
Cash provided by operating activities was 	$4.1 billion 	in the first 	six 	months of 	2020 	compared with 	$4.4 billion 	in the first 	six 	months of 	2019. Cash
provided by operating activities in the first 	six 	months of 2020 includes $1.1 billion of payments
- 	45 	-

-- 46 of 54 --

related to collaborations with AstraZeneca and Eisai compared with $385 million in the first six months of 2019 (see Note 3 to the condensed consolidated
financial statements). Cash provided by operating activities continues to be the Company’s primary source of funds to finance operating needs, capital
expenditures, treasury stock purchases and dividends paid to shareholders.
Cash used in investing activities was 	$2.5 billion 	in the first 	six 	months of 	2020 	compared with 	$2.1 billion 	in the first 	six 	months of 	2019. The increase
was driven primarily by lower proceeds from sales of securities and other investments and higher capital expenditures, partially offset by lower purchases of
securities and other investments and lower use of cash for acquisitions.
Cash used in financing activities was 	$353 million 	in the first 	six 	months of 	2020 	compared with 	$3.7 billion 	in the first 	six 	months of 	2019. The lower
use of cash in financing activities was driven primarily by a net increase in short-term borrowings in 2020 compared with a net decrease in short-term borrowing in
2019, as well as lower purchases of treasury stock, partially offset by higher payments on debt (see below), lower proceeds from the issuance of debt (see below),
higher dividends paid to shareholders, and lower proceeds from the exercise of stock options.
Capital expenditures totaled 	$1.7 billion 	and 	$1.4 billion 	for the first 	six 	months of 	2020 	and 	2019, respectively. The increased capital expenditures
reflect investment in new capital projects focused primarily on increasing manufacturing capacity for Merck’s key products.
The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company
factored 	$1.9 billion 	and 	$2.7 billion 	of accounts receivable in the 	second 	quarter of 	2020 	and the fourth quarter of 	2019, respectively, under these factoring
arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the
Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer
payments related to the factored receivables, which it then remits to the financial institutions. The net cash flows relating to these collections are reported as
financing activities in the Condensed Consolidated Statement of Cash Flows.
Dividends paid to stockholders were 	$3.1 billion 	and 	$2.9 billion 	for the first 	six 	months of 	2020 	and 	2019, respectively. In May 2020, the Board of
Directors declared a quarterly dividend of $0.61 per share on the Company’s common stock for the third quarter that was paid in July 2020. In July 2020, the Board
of Directors declared a quarterly dividend of $0.61 per share on the Company’s common stock for the fourth quarter that will be paid in October 2020.
In February 2020, the Company’s $1.25 billion, 1.85% notes and $700 million floating-rate notes matured in accordance with their terms and were
repaid.
In June 2020, the Company issued 	$4.5 billion 	principal amount of senior unsecured notes consisting of 	$1.0 billion 	of 	0.75% 	notes due 2026, 	$1.25
billion 	of 	1.45% 	notes due 2030, 	$1.0 billion 	of 	2.35% 	notes due 2040 and 	$1.25 billion 	of 	2.45% 	notes due 2050. Merck intends to use the net proceeds from the
offering for general corporate purposes, including without limitation the repayment of outstanding commercial paper borrowings and other indebtedness with
upcoming maturities.
In March 2019, the Company issued $5.0 billion principal amount of senior unsecured notes consisting of $750 million of 2.90% notes due 2024, $1.75
billion of 3.40% notes due 2029, $1.0 billion of 3.90% notes due 2039, and $1.5 billion of 4.00% notes due 2049. The Company used the net proceeds from the
offering of $5.0 billion for general corporate purposes, including the repayment of outstanding commercial paper borrowings.
In 2018, Merck’s Board of Directors authorized purchases of up to $10 billion of Merck’s common stock for its treasury. The treasury stock purchase
authorization has no time limit and will be made over time in open-market transactions, block transactions on or off an exchange, or in privately negotiated
transactions. During the first 	six 	months of 	2020, the Company purchased 	$1.3 billion 	(16 million 	shares) of its common stock for its treasury under this share
repurchase program. As of 	June 30, 2020, the Company’s remaining share repurchase authorization was $5.9 billion. In March 2020, the Company temporarily
suspended its share repurchase program.
The Company has a $6.0 billion credit facility that matures in June 2024. The facility provides backup liquidity for the Company’s commercial paper
borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.
Critical Accounting Policies
The Company’s significant accounting policies, which include management’s best estimates and judgments, are included in Note 2 to the consolidated
financial statements for the year ended 	December 31, 2019 	included in Merck’s Form 10‑K filed on February 26, 2020. Certain of these accounting policies are
considered critical as disclosed in the Critical Accounting Policies section of Management’s Discussion and Analysis of Financial Condition and Results of
Operations included in Merck’s Form 10-K because of the potential for a significant impact on the financial statements due to the inherent uncertainty in such
estimates. There have been no significant changes in the Company’s critical accounting policies since 	December 31, 2019. See
- 	46 	-

-- 47 of 54 --

Note 1 to the condensed consolidated financial statements for information on the adoption of new accounting standards during 	2020.
Recently Issued Accounting Standards
For a discussion of recently issued accounting standards, see Note 1 to the condensed consolidated financial statements.
Item 4. Controls and Procedures
Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the
Company’s disclosure controls and procedures over financial reporting. Based on their evaluation, the Company’s Chief Executive Officer and Chief Financial
Officer have concluded that as of 	June 30, 2020, the Company’s disclosure controls and procedures are effective. For the 	second 	quarter of 	2020, there were no
changes in internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company’s internal control over
financial reporting.
CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS
This report and other written reports and oral statements made from time to time by the Company may contain so-called “forward-looking statements,”
all of which are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially from those set
forth in the statements. One can identify these forward-looking statements by their use of words such as “anticipates,” “expects,” “plans,” “will,” “estimates,”
“forecasts,” “projects” and other words of similar meaning, or negative variations of any of the foregoing. One can also identify them by the fact that they do not
relate strictly to historical or current facts. These statements are likely to address the Company’s growth strategy, financial results, product development, product
approvals, product potential and development programs. One must carefully consider any such statement and should understand that many factors could cause
actual results to differ materially from the Company’s forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks
and uncertainties, including the impact of the recent global outbreak of COVID-19 and other risks and uncertainties some that are known and some that are not. No
forward-looking statement can be guaranteed and actual future results may vary materially.
The Company does not assume the obligation to update any forward-looking statement. One should carefully evaluate such statements in light of
factors, including risk factors, described in the Company’s filings with the Securities and Exchange Commission, especially on Forms 10-K, 10-Q and 8-K. In
Item 1A. “Risk Factors” of the Company’s Annual Report on Form 10‑K for the year ended 	December 31, 2019, as filed on February 26, 2020, in the Company’s
Form 10-Q for the quarterly period ended March 31, 2020, as filed on May 6, 2020, and in this Form 10-Q, the Company discusses in more detail various important
risk factors that could cause actual results to differ from expected or historic results. The Company notes these factors for investors as permitted by the Private
Securities Litigation Reform Act of 1995. One should understand that it is not possible to predict or identify all such factors. Consequently, the reader should not
consider any such list to be a complete statement of all potential risks or uncertainties.
PART II - Other Information
Item 1. Legal Proceedings
The information called for by this Item is incorporated herein by reference to Note 8 included in Part I, Item 1, Financial Statements (unaudited) —
Notes to Condensed Consolidated Financial Statements.
Item 1A. Risk Factors
For a discussion of risks that affect the Company’s business, please refer to Part I, Item IA, “Risk Factors” in the Company’s Annual Report on Form
10-K for the year ended December 31, 2019. There have been no material changes to the risk factors as previously disclosed in the Company’s Annual Report on
Form 10-K, except as follows:
The global COVID-19 pandemic is having an adverse impact on the Company’s business, operations and financial performance. The Company
is unable to predict the full extent to which the pandemic and related impacts will continue to adversely impact its business, operations, financial
performance, results of operations, and financial condition.
The Company’s business and financial results have been negatively impacted by the outbreak of Coronavirus Disease 2019 (COVID-19). The duration,
spread and severity of the COVID-19 pandemic is uncertain, rapidly changing and difficult to predict. The degree to which COVID-19 impacts the Company’s
results will depend on future developments, beyond the Company’s knowledge or control, including, but not limited to, the duration and spread of the outbreak, its
severity, the actions taken to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume.
- 	47 	-

-- 48 of 54 --

While the Company expects to rely on governmental authorities to determine when operations can return to normal, and is cognizant that the duration,
spread and severity of the outbreak will be critical determinants for purposes of the full-year estimates provided below, Merck has assumed that the majority of the
negative impact occurred in the second quarter of 2020, with a gradual recovery having commenced in the second quarter and extending through the third quarter,
with a return to normal operating levels in the fourth quarter of 2020. To the extent these assumptions prove to be incorrect, the Company’s results may differ
materially from the estimates set forth herein.
Thus far in 2020, the COVID-19 pandemic has impacted the Company’s business and the Company continues to expect that it will impact the business
in numerous ways, including but not limited to those outlined below:
In the second quarter of 2020, the negative impact of the COVID-19 pandemic to Merck’s sales was estimated to be $1.6 billion, including
approximately $1.5 billion for Pharmaceutical revenue and approximately $100 million for Animal Health revenue. The impact to sales in the first quarter of 2020
was immaterial. For the full-year 2020, Merck expects an unfavorable impact to sales of approximately $1.95 billion (excluding the impact of foreign exchange)
due to the COVID-19 pandemic, comprised of approximately $1.8 billion for Pharmaceutical revenue and approximately $150 million for Animal Health revenue.
These estimates include the impacts for the first half of the year.
Roughly two-thirds of Merck’s Pharmaceutical revenue is comprised of physician-administered products, which, despite strong underlying demand,
were affected by social distancing measures, fewer well visits and delays in elective surgeries due to the COVID-19 pandemic. These impacts, as well as the
prioritization of COVID-19 patients at health care providers, have resulted in reduced administration of many of the Company’s human health products, in
particular for its vaccines as well as for 	Keytruda 	and 	Implanon/Nexplanon. The Company anticipates reduced demand for its physician-administered products
while pandemic-related access measures remain in place. In addition, declines in medical visits and elective surgeries also negatively affected the demand for
certain products, including 	Bridion. In Merck’s Animal Health business, reduced veterinary visits and lower demand for protein and milk due to restaurant and
school closures have negatively affected sales.
Operating expenses were positively impacted in the second quarter and first six months of 2020 by approximately $325 million and $425 million,
respectively, primarily driven by lower promotional and selling costs, as well as lower research and development expenses due to the COVID-19 pandemic. For the
full-year 2020, Merck continues to expect a net favorable impact to operating expenses of approximately $400 million including both the favorable impact of lower
spending, largely reflected in the first half of 2020, partially offset by anticipated spending on recently initiated COVID-19-related vaccine and antiviral research
programs.
Item 6. Exhibits
Number 	Description
3.1 	— 	Restated Certificate of Incorporation of Merck & Co., Inc. (November 3, 2009) – Incorporated by reference to Current Report on Form 8-
K filed on November 4, 2009 (No. 1-6571)
3.2 	— 	By-Laws of Merck & Co., Inc. (effective July 22, 2015) – Incorporated by reference to Current Report on Form 8-K filed on July 28,
2015 (No. 1-6571)
31.1 	— 	Rule 13a – 14(a)/15d – 14(a) Certification of Chief Executive Officer
31.2 	— 	Rule 13a – 14(a)/15d – 14(a) Certification of Chief Financial Officer
32.1 	— 	Section 1350 Certification of Chief Executive Officer
32.2 	— 	Section 1350 Certification of Chief Financial Officer
101.INS 	— 	XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded
within the Inline XBRL document.
101.SCH 	— 	XBRL Taxonomy Extension Schema Document.
101.CAL 	— 	XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF 	— 	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB 	— 	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE 	— 	XBRL Taxonomy Extension Presentation Linkbase Document.
104 	— 	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
- 	48 	-

-- 49 of 54 --

Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
MERCK & CO., INC.
Date: August 5, 2020 	/s/ Jennifer Zachary
JENNIFER ZACHARY
Executive Vice President and General Counsel
Date: August 5, 2020 	/s/ Rita A. Karachun
RITA A. KARACHUN
Senior Vice President Finance - Global Controller
- 	49 	-

-- 50 of 54 --

Exhibit 31.1
CERTIFICATION
I, Kenneth C. Frazier, certify that:
1. 	I have reviewed this quarterly report on Form 10-Q of Merck & Co., Inc.;
2. 	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. 	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. 	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:
a) 	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;
b) 	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;
c) 	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) 	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal
quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. 	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) 	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely
to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) 	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over
financial reporting.
Date: 	August 5, 2020
By: 	/s/ Kenneth C. Frazier
KENNETH C. FRAZIER
Chairman, President and Chief Executive Officer

-- 51 of 54 --

Exhibit 31.2
CERTIFICATION
I, Robert M. Davis, certify that:
1. 	I have reviewed this quarterly report on Form 10-Q of Merck & Co., Inc.;
2. 	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. 	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. 	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:
a) 	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;
b) 	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;
c) 	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) 	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal
quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. 	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) 	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely
to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) 	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over
financial reporting.
Date: 	August 5, 2020
By: 	/s/ Robert M. Davis
ROBERT M. DAVIS
Executive Vice President, Global Services
and Chief Financial Officer

-- 52 of 54 --

Exhibit 32.1
Section 1350
Certification of Chief Executive Officer
Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the “Company”), hereby certifies that the Company's Quarterly Report
on Form 10-Q for the quarter ended 	June 30, 2020 	(the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of
1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: August 5, 2020 	/s/ Kenneth C. Frazier
Name:
Title:
KENNETH C. FRAZIER
Chairman, President and Chief Executive Officer

-- 53 of 54 --

Exhibit 32.2
Section 1350
Certification of Chief Financial Officer
Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the “Company”), hereby certifies that the Company's Quarterly Report
on Form 10-Q for the quarter ended 	June 30, 2020 	(the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of
1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: August 5, 2020 	/s/ Robert M. Davis
Name:
Title:
ROBERT M. DAVIS
Executive Vice President, Global Services
and Chief Financial Officer

-- 54 of 54 --